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Abstract——Various lines of evidence indicate the
presence of progressive pathophysiological processes
occurring within the brains of patients with schizophre-
nia. By modulating chemical neurotransmission, anti-
psychotic drugs may influence a variety of functions
regulating neuronal resilience and viability and have
the potential for neuroprotection. This article reviews
the current literature describing preclinical and clinical
studies that evaluate the efficacy of antipsychotic drugs,
their mechanism of action and the potential of first- and
second-generation antipsychotic drugs to exert effects
on cellular processes that may be neuroprotective in
schizophrenia. The evidence to date suggests that al-
though all antipsychotic drugs have the ability to reduce
psychotic symptoms via D2 receptor antagonism, some
antipsychotics may differ in other pharmacological
properties and their capacities to mitigate and possibly
reverse cellular processes that may underlie the patho-
physiology of schizophrenia.
I. Introduction
Our understanding of the pathophysiology of schizo-
phrenia has increased as knowledge of the molecular,
cellular, and systems biology of brain function has ad-
vanced. Beginning with the dopamine (DA1) hypothesis
1Abbreviations: DA, dopamine; 1H-MRS, proton magnetic resonance
spectroscopy; 5-HT, serotonin, 5-hydroxytryptamine; A10, ventral teg-
mental area; A9, nigrostriatal; AC, adenylyl cyclase; ACh, acetylcho-
line; ALLO, allopregnanolone, 3-hydroxy-5-pregnan-20-one; AMPA,
-amino3-hydroxy-5-methyl-4-isoxazole propionic acid; APD, antipsy-
chotic drug; BrdU, bromodeoxyuridine; ChAT, choline acetyltrans-
ferase; CREB, cAMP-response element-binding protein; CSF, cerebro-
spinal fluid; DAAO, D-amino acid oxidase; DARPP-32, dopamine- and
an adenosine 3,5-monophosphate-regulated phospho-protein of 32
kDa; DD, drug discrimination; DHEA, dehydroepiandrosterone; DOPA,
3,4-dihydroxyphenylalanine; EAAT, excitatory amino acid transporter;
EPO, erythropoietin; EPOr, erythropoietin receptor; EPS, extrapyrami-
dal symptoms; EPSPs, excitatory postsynaptic potentials; ERK, extra-
cellular-regulated kinase; FGA, first-generation antipsychotic drug;
FRT, forelimb retraction time; GAD, glutamic acid decarboxylase;
GAT, GABA transporter; GLUT, glucose transporter; GPCR, G-
protein-coupled receptor; GSK-3, glycogen synthase kinase-3; HRT,
hind limb retraction time; IP3, inositol triphosphate; LY294002,
2-(4-morpholinyl)-8-phenyl-1(4H)-benzopyran-4-one hydrochloride;
M100907, [R-()-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenylethyl)]-
4-piperidine-methanol]; MAP, mitogen-activated protein; MCT,
monocarboxylate transporter; mGlu, metabotropic glutamate recep-
tors; MK-801, dizocilpine, 5H-dibenzo[a,d]cyclohepten-5,10-imine
(dizocilpine maleate); MPP, 1-methyl-4-phenylpyridinium ion;
NAAG, N-acetylaspartylglutamate; NGF, nerve growth factor,
BDNF, brain-derived neurotrophic factor, FGF, fibroblast growth
factor; NMDA, N-methyl-D-aspartic acid; NRG1, neuroregulin-1;
NT-3, neurotrophin-3; PCP, phencyclidine; PD98059, 2-amino-3-
methoxyflavone; PFC, prefrontal cortex; PK, protein kinase; PLC,
phospholipase C; PPI, prepulse inhibition; PV, parvalbumin; RGS,
regulators of G-protein signaling; SGA, second-generation antipsy-
chotic drug; SOD, superoxide dismutase; SR46349B, eplivanserin;
SST, somatostatin; TD, tardive dyskinesia.
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of schizophrenia, we now have more sophisticated and
powerful ways of modeling the pathophysiology of
schizophrenia. With this enhanced capacity to conceptu-
alize the disease, we have acquired the ability to exam-
ine the actions of therapeutic agents at a variety of
levels and to discern any differences that may exist
among them. Ultimately, in controlled clinical trials, the
clinical relevance of such differences can be tested.
Although some debate exists as to whether schizo-
phrenia is wholly neurodevelopmental in nature, there
is evidence supporting a progressive and possibly neu-
rodegenerative process as well. “Neuroprotection” refers
to therapies that help to maintain the structural integ-
rity and normal functioning of the central nervous sys-
tem in response to a pathological process and conse-
quent neurobiological stress. Therapies that may be
neuroprotective will probably encompass the mitigation
and/or possible reversal of a broad range of anatomical,
physiological, and molecular processes thought to under-
lie the pathophysiology of schizophrenia.
There is increasing interest in understanding not only
the manner through which antipsychotic drugs (APDs)
are believed to play an important role in modulating
dysfunction in chemical neurotransmission to control
the symptoms of schizophrenia but also their potential
role for neuroprotection. The first-generation antipsy-
chotic drugs (FGAs) treat some of the symptoms of
schizophrenia including delusions and hallucinations
but, depending on their potency and the dose used, can
have substantial side effects, including effects on the
extrapyramidal system in the form of extrapyramidal
signs (EPS) and tardive dyskinesia (TD) and hyperpro-
lactinemia. The second-generation antipsychotic drugs
(SGAs) also reduce the positive symptoms of schizophre-
nia, but with less EPS and TD and, in general, reduced
hyperprolactinemia as well. However, most SGAs tend
to cause weight gain and disturbances in glucose and
lipid metabolism.
Research also suggests that some of the SGAs may
have additional therapeutic properties including cogni-
tive enhancement, reduction of negative symptoms, en-
hanced relapse prevention, and prevention of disease
progression and clinical deterioration, although these
effects have not been consistently or definitively demon-
strated. Presumably, the differential therapeutic effects
of SGAs are due to some distinct pharmacological prop-
erties. Heretofore, theories of the mechanism of action of
APDs have focused on drug effects on dopamine recep-
tors and to a lesser extent on other neuroreceptors in-
cluding those for serotonin (5-HT1A,2A,2C,3,6,7) and nor-
epinephrine (1,2) (Miyamoto et al., 2005).
Recently, a growing body of evidence derived from
nontraditional assays and paradigms used to study
APDs has demonstrated that specific SGAs induce ef-
fects in a range of cellular and molecular assays that
suggest unique therapeutic targets (not shared by all
SGAs and FGAs) beyond the antagonism of DA neuro-
transmission. These include in vitro and whole animal
studies, which show that some SGAs may increase or
preserve neurotrophic factor levels, neurogenesis, neu-
ronal plasticity, mitochondrial biogenesis, cell energet-
ics, and antioxidant defense enzymes. Furthermore,
some SGAs may uniquely protect against N-methyl-D-
aspartic acid (NMDA) antagonist-induced neurotoxicity
and the consequent behavioral effects. Recent findings of
the ability of specific SGAs to ameliorate the loss of gray
matter in patients in the early stages of schizophrenia
further support the hypothesis of unique pharmacologi-
cal properties and therapeutic benefits (Lieberman et
al., 2005b; van Haren et al., 2007).
These putative properties of select SGAs have become
more relevant in light of the increasing acceptance by
the field of a progressive pathophysiological process and
possibly neurodegenerative process coincident with (or
shortly before) the onset of the illness that may underlie
the clinical deterioration that occurs in many patients
with schizophrenia (Wyatt, 1991; DeLisi et al., 1997;
Csernansky and Bardgett, 1998; Woods, 1998; Lieber-
man, 1999). In this article we will critically review stud-
ies of the effects of FGAs and SGAs on a number of
processes pertinent to the neurobiology and pharmaco-
therapy of schizophrenia.
II. Pathophysiology of Schizophrenia
Schizophrenia has been characterized as both a neu-
rodegenerative and neurodevelopmental disorder. Kra-
epelin proposed in the early 1900s that schizophrenia
was a degenerative disease in which a patient’s deteri-
oration occurred after the onset of the illness marked by
mental symptoms after what seemed to be a relatively
normal childhood. However, more recent research has
emphasized the role of genes and their effects, along
with environmental factors, on neurodevelopment as
producing the diathesis from which schizophrenia
arises. Numerous genetic association and linkage stud-
ies have implicated genetic variants within many com-
ponents of each neurotransmitter system in the patho-
physiology of schizophrenia, although not without
controversy (for review, see Riley and Kendler, 2006;
Catapano and Manji, 2007; Eisener et al., 2007; Lang et
al., 2007), leading to compensatory changes and alter-
ations in brain development. However, it has been pro-
posed that distinct pathological processes may underlie
the various clinical stages of the illness with neurode-
velopmental mechanisms underlying the premorbid
phase of the illness and a progressive pathophysiological
process beginning with neurochemical dysregulation
that can lead to neurodegeneration occurring after the
formal onset of the illness and possibly beginning in its
prodromal stage (for review, see Wyatt, 1991; DeLisi et
al., 1997; Csernansky and Bardgett, 1998; Woods, 1998;
Lieberman, 1999; Lieberman et al., 2001b, 2006) (Fig. 1).
360 LIEBERMAN ET AL.
It seems likely that if there are distinct pathophysiolog-
ical stages of schizophrenia, the clinical manifestations
of the illness derive from some process involving dys-
regulation in chemical neurotransmission of genetically
susceptible neural pathways (Lieberman et al., 2001b).
A. Neurotransmitter Dysregulation
Although dopamine has been predominant, schizo-
phrenia has been associated with dysregulation of many
neurotransmitter systems including GABA, glutamate,
serotonin, noradrenaline, and acetylcholine in addition
to dopamine. Dysregulation has been observed at many
different levels including neurotransmitter synthesis,
storage, release, reuptake and inactivation, metabolism,
number and structure of presynaptic/postsynaptic re-
ceptors, functioning of receptors as high or low affinity,
number of transporters, and alterations at the level of
postreceptor signaling pathways.
There are two major categories of neurotransmitter
receptors: 1) iontropic receptors and 2) G-protein-cou-
pled or metabotropic receptors. Iontropic receptors are
ligand-gated ion channels that regulate ionic currents
and membrane potential and include glutamatergic re-
ceptors as the predominant excitatory receptors and
GABAergic receptors as the predominant inhibitory re-
ceptors within the brain. Additional iontropic excitatory
receptors include the nicotinic acetylcholine receptor
and the serotonergic 5-HT3 receptor. Metabotropic recep-
tors involve coupling to various G-proteins leading to the
regulation of cAMP and inositol triphosphate (IP3) sec-
ond messengers and subsequent downstream signaling
systems including kinase cascades and transcriptional
factors. The metabotropic receptors include members of
the dopamine, glutamate, serotonin, acetylcholine, and
noradrenaline neurotransmitter systems. Ligand-gated
ion channels are thought to reflect fast synaptic neuro-
transmission and to account for quasi-instantaneous
functioning within the brain, whereas metabotropic re-
ceptors are slower-acting and are thought to be essential
for neuromodulation and long-term regulation (Girault
and Greengard, 2004).
The molecular changes observed in each of these neu-
rotransmitter systems occur within discrete neurocir-
cuits within the brain thought to underlie the various
symptom profiles observed in patients with schizophre-
nia, including positive symptoms, negative symptoms,
cognitive dysfunction, anxiety, depression, and agita-
tion. Although discussion of the specific details of these
neurocircuits is out of the scope of this review, dysfunc-
tion of neurotransmitter regulation in schizophrenia has
been observed across multiple brain regions, reflecting
distinct neurocircuits [reviews of specific brain circuits:
FIG. 1. Overview of the possible mechanisms of neurodegeneration occurring in schizophrenia. Italic denotes potential areas of intervention by
antipsychotic drugs.
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basal ganglia-thalamo-cortical loops (Alexander et al.,
1986), amygdalo-entorrhinal inputs to hippocampus
(Benes and Berretta, 2000), and basal ganglia and cer-
ebellar loops (Middleton and Strick, 2000); reviews of
specific brain regions: basal ganglia (Tisch et al., 2004)
and thalamus (Clinton and Meador-Woodruff, 2004)].
In addition, altered regulation at the level of mole-
cules and neurocircuits is thought to underlie alter-
ations in complex brain processes. In this regard, schizo-
phrenia has been conceptualized as a disease
characterized by abnormal information processing that
occurs within subcortical and cortical regions, including
sensory gating deficits at the level of the thalamus and
altered desynchronization of modal or supramodal cor-
tical associative functions (for review, see Braus et al.,
2002). Related to the “abnormal information processing”
concept, schizophrenia has been associated with abnor-
malities in neural oscillations, an “emergent property” of
neural networks arising from temporal synchrony be-
tween synaptic transmission and the firing of distinct
neuronal populations (Ford et al., 2007).
We will focus primarily on the dopaminergic,
GABAergic, and glutamatergic neurotransmitter sys-
tems, although references to other systems will be made.
As a review, several of the molecules involved in signal-
ing cascades associated with neurotransmitter-receptor
interactions and that of other molecules are summarized
in Fig. 2.
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kinases; GSH-Px, glutathione peroxidase; H2O2, hydrogen peroxide; IPSP, inhibitory postsynaptic potential; KYN, kynurenic acid; M, muscarinic
acetylcholine receptors; MAPK, mitogen-activated protein kinase; mTOR, mammalian target of rapamycin; nAChR, nicotinic acetylcholine receptor;
NE, norepinephrine; NS, neuroactive steroids; O2-, superoxide radical; -OH, hydroxyl anion; P, phosphorylation; PI3K, phosphatidylinositol 3-kinase;
PIP3, phosphatidylinositol triphosphate; PP2A, protein phosphatase 2A; T, transporter protein; Vit, vitamin.
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1. Dopamine. One of the most popular theories un-
derlying the pathophysiology of schizophrenia involves
increased dopaminergic activity within the mesolimbic
dopamine system thought to underlie the positive or
psychotic symptoms of schizophrenia and decreased do-
paminergic activity within the mesocortical dopamine
system thought to reflect negative symptoms and cogni-
tive dysfunction also seen in schizophrenia (for reviews,
see Abi-Dargham and Moore, 2003; Guillin et al., 2007;
Meisenzahl et al., 2007). In line with this theory, all
currently available APDs reduce psychotic symptoms
via blockade of dopamine neurotransmission within the
striatal complex of the mesolimbic pathways.
Dopamine is synthesized from tyrosine to DOPA via
tyrosine hydroxylase and then to dopamine via DOPA
decarboxylase, reactions occurring within two major cell
groups, substantia nigra pars compacta projecting to the
striatum and the ventral tegmental area projecting to
the ventral striatum and cerebral cortex. There are five
metabotropic dopamine receptors divided into two major
classes: D1-like receptors (D1 and D5) and D2-like recep-
tors (D2–4). Two enzymes are responsible for the cata-
bolic inactivation of dopamine, different isozymes of
monoamine oxidase (MAO-A and MAO-B) and catechol-
O-methyltransferase. In addition, dopamine released
from presynaptic terminals is recaptured into presynap-
tic terminals via the dopamine transporter.
All antipsychotics to date act as antagonists (or par-
tial agonists) at the D2 receptor, and most show a dose-
dependent threshold of D2 receptor occupancy for their
therapeutic effects (Kapur and Mamo, 2003). Although
individual studies report contradictory findings, a meta-
analysis of 13 in vivo studies demonstrated a 12% in-
crease in D2 receptor binding in drug-naive and in drug-
free patients with schizophrenia, providing limited
support for D2 receptor up-regulation and supersensitiv-
ity in schizophrenia (Laruelle, 1998). Seeman et al.
(2006) have suggested that elevations in the high-affin-
ity state of dopamine D2 receptors (D2
High receptors)
may reflect a common point of convergence among the
various pathways for eliciting psychosis. They indicated
that many of the causes of psychosis in adult humans
such as drugs, steroids, ethanol, and brain lesions lead
to dopamine supersensitivity in rats and to an increase
in the high-affinity state of dopamine D2
High receptors in
striata (Seeman et al., 2006). Other proposed links be-
tween dopamine D2 neurotransmission and schizophre-
nia include polymorphisms in the D2 receptor gene (for
review, see Lang et al., 2007) and alterations in the
components of the post-dopamine D2 receptor signaling
cascade discussed in section II.A.5. However, because
APDs can up-regulate D2 receptors, the possibility of a
treatment effect and drug artifact must be considered.
Whereas the D2 receptor plays a predominant role in
the current treatment of psychotic symptoms, other com-
ponents of the dopamine neurotransmitter system have
been implicated in schizophrenia. These include the D1
receptor (Abi-Dargham and Moore, 2003; Goldman-Ra-
kic et al., 2004), D3 receptor (Micheli and Heidbreder,
2006), D4 receptor (Kra¨mer et al., 2007), catechol-O-
methyltransferase (Kra¨mer et al., 2007; Lewandowski,
2007), dopamine transporter (Schmitt et al., 2006; Ma-
teos et al., 2007), dopamine receptor-interacting pro-
teins calcyon and neuronal Ca2 sensor 1 (Bergson et
al., 2003), and dopamine receptor-adenosine receptor
interactions (Fuxe et al., 2007).
2. GABA. GABAergic synapses are the key inhibi-
tory synapses within the brain, and decreased GABAer-
gic neurotransmission has been implicated in the patho-
physiology of schizophrenia (for review, see Benes and
Berretta, 2001; Blum and Mann, 2002; Wassef et al.,
2003; Lewis et al., 2004; Guidotti et al., 2005). It has
been proposed that deficits in GABAergic neurotrans-
mission may result in an imbalance between excitatory
and inhibitory neurotransmission, favoring excitation
and possible excitotoxicity. Olney et al. (1999) suggested
that a developmental deficit of inhibitory GABA inter-
neurons may set the stage for ongoing neurodegenera-
tion through the uncontrolled activation of glutamater-
gic neurons. In addition, GABAergic interneurons play
an important role in regulating pyramidal neuron firing
rates (McBain and Fisahn, 2001), and, as a result, re-
duced GABAergic function would alter the synchronous
firing patterns of cortical neurons, which may underlie
information-processing deficits known to be present in
patients with schizophrenia (Hajo´s, 2006).
GABA is synthesized from glutamate via two molecu-
lar forms of glutamic acid decarboxylase (GAD67 and
GAD65). GABAergic neurons (or interneurons) coexpress
specific proteins and can be classified by location within
specific neuronal circuits based on the expression of
these proteins—reelin, parvalbumin (PV), and calreti-
nin. Reelin is an extracellular matrix protein constitu-
tively released from GABAergic terminals that binds to
integrin receptors to regulate synaptic plasticity (e.g.,
long-term potentiation) and protein synthesis within
neuronal dendrites and spines. PV and calretinin are
calcium-binding proteins that probably contribute to in-
tracellular Ca2 signaling cascades. Three GABA recep-
tors have been identified thus far: GABAA and GABAC
receptors are iontropic receptors, whereas the GABAB
receptor is metabotropic and coupled to a GTP-binding
protein. The GABAA receptor is a heteropentameric
structure consisting of various subtypes composed of at
least 16 different GABAA receptor subunits—six , four
, three , one , one , and one  (Mohler et al., 1995;
Whiting, 2003). The  subunits of the GABAA receptor
confer different affinities for GABA, and these subunits
show a very specialized regional cellular and subcellular
distribution. In addition, a subset of GABAA receptors
contain a binding site for benzodiazepines. The benzodi-
azepine binding site on the GABAA receptor is alloster-
ically coupled to the GABA binding site, resulting in
increased receptor occupancy at low GABA concentra-
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tions that increases the frequency of channel openings
(Pritchett et al., 1989). GABA neurotransmission is ter-
minated via reuptake by GABA transporter proteins.
GABAergic dysfunction in schizophrenia has been
characterized as a reduction in the availability of GABA
and related proteins presynaptically and compensatory
up-regulation of GABA receptors postsynaptically. Most
studies have reported low GABA levels in at least some
brain regions in patients with schizophrenia, although
there is no clear consensus on the specific brain loci
affected with the exception of the amygdala. At the
presynaptic level, down-regulation of mRNA and/or pro-
tein for GAD67, reelin, and PV has been observed in
postmortem brain tissues of patients with schizophre-
nia. Lower levels of the GABA transporter 1 (GAT1)
have also been observed, which may reflect a compensa-
tory change in response to low GABA levels.
Within the cerebral cortex and hippocampus, there is
evidence for fewer GABAergic interneurons, although
this reduction is localized primarily to cortical layer II.
Several authors have suggested that the loss of this
subset of GABAergic neurons is probably not sufficient
to support the reductions observed in GAD67, reelin, and
GAT1 (for review, see Guidotti et al., 2005), implying
that other mechanisms such as promoter-related down-
regulation of gene expression must be involved. Recent
work has demonstrated an increase in DNA-methyl-
transferase-1 expression within select GABAergic inter-
neurons in postmortem schizophrenia brains that could
underlie down-regulation of gene expression (Veldic et
al., 2004, 2005). Other work focusing on the chandelier
class of GABAergic neurons that form distinctive verti-
cal arrays called “cartridges” of synaptic terminals along
the axon initial segments of pyramidal neurons found no
differences in the relative density, laminar distribution,
or size of parvalbumin-containing neurons (Lewis,
2000). However, the density of GAT1-immunoreactive
chandelier neuronal axon cartridges was decreased by
40% in subjects with schizophrenia compared with
healthy control subjects and subjects with other psychi-
atric disorders (Lewis, 2000).
At the postsynaptic level, the majority of data support
increased expression of GABAA receptors in schizophre-
nia. The numbers of GABAA receptors labeled by
[3H]muscimol (which labels all GABA receptors) in the
prefrontal cortex (Hanada et al., 1987; Benes et al.,
1996b), superior temporal gyrus (Deng and Huang,
2006), and hippocampus (Benes et al., 1996a; Benes,
1997) are increased in postmortem brain tissue of pa-
tients with schizophrenia. In contrast, the numbers of
GABAA receptors with benzodiazepine-binding sites la-
beled by [3H]flunitrazepam are reduced or unchanged in
prefrontal cortex (Pandey et al., 1997) and hippocampus
(Squires et al., 1993; Benes et al., 1996a) of schizophre-
nia brains. Subsequent work has demonstrated up-reg-
ulation of mRNAs and proteins for 1 and 5 subunits
within the prefrontal cortex. The 5 subunit confers a 3-
to 10-fold higher affinity for GABA than that observed
for the 1-containing receptor, suggesting increases in
GABAA receptors with a higher affinity for GABA.
The data implicating the GABAB receptor in the
pathophysiology of schizophrenia are more limited.
There is evidence for a reduction in GABAB receptor
immunoreactivity in the entorhinal cortex and inferior
temporal cortex of the brain in schizophrenia (Mizukami
et al., 2002). In addition, baclofen, a GABAB agonist, can
reverse spontaneous gating deficits in animal models of
schizophrenia (Bortolato et al., 2007).
Somatostatin (SST) is a neuropeptide present in a
subpopulation of GABA neurons, and a reduction in the
density of neurons positive for SST as well as expression
of SST mRNA per neuron is seen in dorsolateral prefron-
tal cortex in schizophrenia (Morris et al., 2008). There is
evidence that neuroregulin-1 (NRG1) may regulate
GABAergic neurotransmission via binding to presynap-
tic ErbB4 receptors (Woo et al., 2007). NRG1 is a regu-
lator of neural development, and NRG1 and ErbB4 have
been identified as susceptibility genes for schizophrenia
(Britsch, 2007).
Preliminary data using real-time quantitative poly-
merase chain reaction demonstrated that several of
these molecular changes (i.e., decreased transcripts for
SST, PV, GAD67, GAT1, and the 1 and  subunits of
GABAA receptors) are observed within four cortical ar-
eas (dorsolateral prefrontal cortex, anterior cingulate
cortex, and primary motor and visual cortices). This
finding suggests that a conserved set of molecular alter-
ations in GABA neurotransmission may contribute to
the pathophysiology of schizophrenia (Hashimoto et al.,
2008).
3. Glutamate. Glutamatergic synapses are the key
excitatory synapses within the brain, and mechanisms
of both hyperglutamatergic and hypoglutamatergic
functioning have been implicated in the pathophysiology
of schizophrenia (for review, see Olney et al., 1999; Deut-
sch et al., 2001; Coyle, 2006). It has been proposed that
NMDA receptor hypofunction may lead to excessive
stimulation of other iontropic receptors, causing a cas-
cade of excitotoxic events including oxidative stress and
apoptosis (for review, see Deutsch et al., 2001). Dysregu-
lation of glutamateric functioning has been observed
across many components of the glutamate neurotrans-
mission system.
Glutamatergic receptors include both iontropic and
metabotropic receptor subtypes. The iontropic receptors
include NMDA, -amino-3-hydroxy-5-methyl-4-isox-
azole propionic acid (AMPA), and kainate receptors.
Binding of glutamate to these receptors causes Ca2 and
Na entry into neurons, resulting in excitatory postsyn-
aptic potentials and membrane depolarization. In addi-
tion, increased intracellular Ca2 levels activate a num-
ber of signaling cascades (Berridge, 1998). The NMDA
receptor forms a channel allowing for ion influx,
whereas the AMPA and kainate receptors open voltage-
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sensitive ion channels on the cell membrane. The NMDA
receptor is voltage-gated and is blocked by magnesium
and modulated by two coagonists, glycine and D-serine,
as well as by several intracellular and extracellular me-
diators (for review, see Millan, 2005). The NMDA recep-
tor is a heteromeric assembly of an obligatory NR1 sub-
unit (eight distinct isoforms) and a combination of
NR2A, NR2B, NR2C, NR2D, NR3A, and NR3B subunits
(Dingledine et al., 1999; Millan, 2005). The properties of
the NMDA receptor depend on the composition of sub-
units. In the human cortex, NR1, NR2A, and NR2B are
the predominant subunits found (Cull-Candy et al.,
2001). NR2 is the binding site for glutamate and other
mediators, and NR1 is the binding site for glycine and
D-serine (glycine modulatory site) (Johnson and Ascher,
1987). Eight metabotropic glutamate receptors, termed
mGlu1–8, have been cloned and are classified into three
groups based on sequence, identity, and transduction
mechanisms: group I, mGlu1,5, are coupled to Gq protein,
leading to an increase in PLC; group II, mGlu2,3, are
coupled to Gi and Go, leading to a decrease in AC; and
group III, mGlu4,6,7,8, are coupled to Gi and Go, leading
to a decrease in AC. Glutamate neurotransmission is
terminated via excitatory amino acid transporters
(EAATs) expressed on astrocytes, Bergmann glia, and
neurons throughout the brain, and several EAAT-inter-
acting proteins can regulate EAAT activity (for review,
see Huerta et al., 2006).
The NMDA receptor hypofunction hypothesis of
schizophrenia is based on the observation that phencyc-
lidine (PCP), an NMDA antagonist, can induce a spec-
trum of behavioral effects in humans that resemble the
positive, negative, and cognitive symptoms seen in
schizophrenia (Deutsch et al., 1989; Javitt and Zukin,
1991; Coyle, 1996; Tamminga, 1998). All NMDA antag-
onists [including ketamine and MK-801 (dizocilpine)]
tested in humans can trigger a florid psychotic response
similar to that with PCP (for review, see Olney et al.,
1999). In addition, ketamine can precipitate psychoses
in patients with schizophrenia (Lahti et al., 1995, 2001;
Malhotra et al., 1996).
There are numerous indications that NMDA receptor
functioning is reduced in patients with schizophrenia
(for review, see Millan, 2005). Endogenous antagonists
of the NMDA receptor, kynurenic acid and N-acetyl-
aspartyl-glutamate (NAAG), are elevated within the ce-
rebrospinal fluid and/or brain of patients with schizo-
phrenia (Tsai et al., 1995; Coyle, 1996; Schwarcz et al.,
2001; Erhardt et al., 2007). NAAG is also a potent selec-
tive agonist of the mGluR3 metabotropic receptor, which
inhibits glutamate release (Wroblewska et al., 1997),
further limiting NMDA receptor function. Indices of ox-
idative stress are elevated in schizophrenia, which could
lead to reduced activation of the NMDA receptor via
oxidation of the redox-sensitivity site (Smythies, 1999).
Of particular note, the levels of glutathione, an endoge-
nous redox regulator, are reduced in the cerebrospinal
fluid and prefrontal cortex of patients with schizophre-
nia (Do et al., 2000), and expression of two genes respon-
sible for glutathione synthesis is decreased in fibroblasts
of subjects with schizophrenia compared with that in
control subjects (Tosic et al., 2004). Phosphorylation of
the NR1 or NR2 subunits by protein kinases can dra-
matically affect NMDA receptor activity (Dingledine et
al., 1999; Yamakura and Shimoji, 1999; Cull-Candy et
al., 2001), and there is evidence for decreased phosphor-
ylation of the NMDA receptor type 1 subunit at serine
897, a target of protein kinase A, in the brains of pa-
tients with schizophrenia (Emamian et al., 2004).
NMDA receptor activity requires the binding of coago-
nists glycine or D-serine, and alterations in glycine and
D-serine metabolism have been reported in schizophre-
nia (for review, see Boks et al., 2007). Low glycine levels
and low glycine/serine ratios but elevated levels of serine
were observed in medication-free patients with schizo-
phrenia compared with those in healthy control subjects
(Sumiyoshi et al., 2004). Likewise, Neeman et al. (2005)
reported lower glycine levels and glycine/serine ratios in
chronically ill patients with schizophrenia treated with
FGAs or SGAs (Neeman et al., 2005). Of interest, in both
studies, low glycine levels correlated with greater nega-
tive symptomatology (Sumiyoshi et al., 2004; Neeman et
al., 2005). Increased binding to the glycine binding site
has been reported in several cortical regions in schizo-
phrenia (Ishimaru et al., 1992). Grimwood et al. (1999)
reported an increase in the number of glycine binding
sites per NMDA receptor subunits in patients with
schizophrenia. Burnet et al. (2008) reported a reduction
in sodium-coupled neutral amino acid transporter 2, a
possible transporter of glycine, within the dorsolateral
prefrontal cortex and cerebellum of patients with schizo-
phrenia, although no change was observed for the gly-
cine transporter GlyT1 mRNA or protein. Low levels of
D-serine have been observed in patients with schizophre-
nia (Hashimoto et al., 2003, 2005; Yamada et al., 2005),
along with select increases in postmortem tissue in the
activity and/or expression of mRNA for D-amino acid
oxidase (DAAO), the enzyme that degrades D-serine
(Verrall et al., 2007; Madeira et al., 2008). The D-serine
transporter in neurons and glia, Asc-1 protein, was
found to be reduced within the dorsolateral prefrontal
cortex and cerebellum of subjects with schizophrenia
(Burnet et al., 2008). There is evidence for increased
levels of serine racemase, the enzyme that synthesizes
D-serine from L-serine, within the dorsolateral prefron-
tal cortex of patients with schizophrenia (Verrall et al.,
2007). Glycine, D-serine, other glycine modulatory site
agonists, and glycine transport inhibitors show benefit
in treating symptoms in schizophrenia and in animal
models of schizophrenia (for review, see Boks et al.,
2007, Shim et al., 2008).
Alterations in NMDA subunit receptor mRNA expres-
sion have been observed in the brains of patients with
schizophrenia (for review, see Millan, 2005). However,
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there is considerable inconsistency in the observations
that have been made, possibly reflecting variations in
treatment, disease status, outcome measurements, age,
and brain region examined. The majority of findings
suggest a reduction in mRNA for the NR1 subunit
within the thalamus, hippocampus, and cortex, which
would be associated with reduced NMDA receptor func-
tion. Alterations have also been observed in NMDA re-
ceptor binding and in expression of NR2A, NR2B, NR2C,
and NR2D subunits. Of interest, an increase in the
levels of NR1 subunits was observed in the substantia
nigra in schizophrenia (Mueller et al., 2004). Cortical
and subcortical glutamatergic pathways send glutama-
tergic afferents to the substantia nigra and ventroteg-
mental area. The increase in NR1 subunit expression
within the substantia nigra could reflect increased ac-
tivity at NMDA receptors on subcortical dopaminergic
cell bodies that may contribute to the dopaminergic hy-
persensitivity/hyperactivity seen in schizophrenia (for
review, see Millan, 2005).
In animal testing, administration of NMDA antago-
nists results in a number of behavioral, metabolic, and
electrophysiological changes thought to model various
symptoms occurring in patients with schizophrenia (for
review, see Morris et al., 2005; Rujescu et al., 2006;
Mouri et al., 2007). In addition, administration of
NMDA antagonists has been linked to neurodegenera-
tive changes associated with excitotoxicity (Olney et al.,
1999; Deutsch et al., 2001) and apoptosis (Griffiths et al.,
2000; Wang et al., 2000, 2003). Excitotoxicity is thought
to reflect excessive synaptic release of glutamate, over-
stimulation of glutamatergic iontropic receptors leading
to dysregulation of Ca2 homeostasis and subsequent
cell damage (Arundine and Tymianski, 2003). Indeed,
postmortem studies have revealed a number of patho-
logical changes occurring within the brains of patients
with schizophrenia as reviewed in section II.B.
In rodents, blocking of NMDA receptors is associated
with increased release of glutamate within the cerebral
cortex (Moghaddam et al., 1997; Adams and Moghad-
dam, 1998) and nucleus accumbens (Razoux et al.,
2007). However, elevations in glutamate within the pre-
frontal cortex of rodents occurs during short-term ad-
ministration of NMDA antagonists, whereas long-term
administration over 7 consecutive days actually results
in a trend for lower basal levels and lower dialysate
levels of glutamate upon challenge (Zuo et al., 2006).
Thus, excitotoxic events associated with NMDA antago-
nists may be reflected by initial increases in glutama-
tergic neurotransmission that are followed subsequently
and chronically by lower levels.
Studies measuring glutamate levels within patients
with schizophrenia compared with healthy control sub-
jects have shown variable results. In cerebrospinal fluid
(CSF), a reduction in glutamate has been reported (Kim
et al., 1980), although a number of other studies have
reported no change (Perry, 1982; Gattaz et al., 1985;
Tsai et al., 1995; Korpi et al., 1987; Deutsch et al., 1989;
Faustman et al., 1999) in patients with schizophrenia
compared with control subjects. In one of these studies,
cluster analysis had revealed one subgroup of patients
with schizophrenia characterized by low CSF glutamate,
enlarged ventricles, and higher thought disorder,
whereas another was characterized by high CSF gluta-
mate, normal brain structure, and less thought disorder
(Tsai et al., 1995). In another study, ratings of positive
symptoms were inversely correlated with glutamate
concentrations (Faustman et al., 1999). These two stud-
ies suggest that lower glutamate levels may be associ-
ated with greater severity of positive symptoms and
possibly also degenerative changes within the brain. In
postmortem brain tissue, Perry (1982) reported no
change in glutamate levels relative to those of controls,
whereas Tsai et al. (1995) reported a reduction. In blood,
no difference in glutamate levels (Alfredsson and Wiesel,
1989), increased levels of glutamate (Macciardi et al.,
1990; van der Heijden et al., 2004), and reduced levels of
glutamate (Palomino et al., 2007) have been reported.
Studies using short-echo proton magnetic resonance
spectroscopy (1H-MRS) to examine brain glutamate/glu-
tamine levels in vivo revealed significantly higher levels
of glutamine in the left anterior cingulate cortex and
thalamus of neuroleptic-naive patients experiencing
their first episode of schizophrenia compared with those
in healthy control subjects (The´berge et al., 2002). With
use of this “in vivo” approach, significantly lower levels
of glutamine and glutamate were found in the left ante-
rior cingulate cortex of patients with chronic schizophre-
nia than in healthy volunteers, whereas glutamine lev-
els in the left thalamus were higher (The´berge et al.,
2002). Another study using 3-T 1H-MRS reported signif-
icant elevations of glutamate/glutamine levels in the
medial prefrontal cortex of nonpsychotic adolescents at
high genetic risk for schizophrenia compared with those
in low-risk offspring. These subsequent studies provide
tentative support for the proposition that higher levels
of glutamate may be present during the early stages of
the illness followed by lower levels subsequently. How-
ever, many different factors could affect the measure-
ment of glutamate and other excitatory amino acids in
schizophrenia notwithstanding the type of assessment
(i.e., CSF, postmortem tissue, blood, or 3-T 1H-MRS) and
brain region, including the likelihood of compensatory
changes in glutamate and related neurotransmitter sys-
tems over time, effects of medication, response to treat-
ment, active psychosis, subtypes of schizophrenia, and
patients’ current symptom profile.
There is some evidence for regionally selective in-
creases in the density of kainate and AMPA binding
sites in the postmortem brains of patients with schizo-
phrenia (Nishikawa et al., 1983; Toru et al., 1988; Noga
et al., 1997), although not all studies have shown in-
creased binding (Kurumaji et al., 1992; Healy et al.,
1998). In addition, there is evidence for decreased ex-
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pression of the neuronal transporter (EAAT3) in schizo-
phrenia (McCullumsmith and Meador-Woodruff, 2002),
but increased levels of expression of the glial EAAT
transporter in medication-free patients (Matute et al.,
2005). Increased expression of EAAT-interacting pro-
teins has been observed within the thalamus (Huerta et
al., 2006). There is evidence for dysfunction of the astro-
cytic neuropeptidase glutamate carboxypeptidase II, the
dipeptidase that hydrolyzes NAAG into glutamate and
N-acetylaspartate, which could contribute to NMDA re-
ceptor hypoactivity (Carlsson and Carlsson, 1990; Olney
and Farber, 1995; Coyle, 1996). These collective findings
suggest that glutamate signaling is impaired in schizo-
phrenia, although the mechanisms of regulation are
complex.
Several authors have proposed a model of the neuro-
anatomical circuitry within the cerebral cortex that may
be altered in the brains of patients with schizophrenia
(for review, see Olney et al., 1999): Stimulation of
NMDA receptors on the GABAergic inhibitory interneu-
rons within the cortex leads to the release of GABA,
which acts upon GABA-gated chloride ion channels
(GABAA receptor complex) to inhibit glutamatergic neu-
rons and the release of glutamate. Blockade of NMDA
receptors would therefore decrease GABAergic inhibi-
tory tone and result in heightened activity of glutama-
tergic neurons within the cortex and at their terminal
fields. In rat, administration of dizocilpine, a selective
NMDA antagonist, can decrease the amplitude and fre-
quency of excitatory postsynaptic currents in GABAergic
interneurons and inhibitory postsynaptic currents in py-
ramidal neurons and from the rat cerebral cortex (Li et
al., 2002), a finding consistent with reduced GABAergic
inhibitory tone.
NMDA antagonists can also up-regulate dopamine
neurotransmission. In addition, blocking of NMDA re-
ceptors is associated with dopamine release within the
cerebral cortex in rodents (Moghaddam et al., 1997; Ad-
ams and Moghaddam, 1998). Increased mesolimbic do-
paminergic responsivity and stress- and psychostimu-
lant-induced hyperlocomotion have been observed after
subchronic PCP administration (Jentsch et al., 1998). It
has been suggested that NMDA receptor hypofunction
may actually precede the dopaminergic alterations ob-
served in schizophrenia.
4. Other—Serotonin, Acetylcholine, Norepinephrine.
Whereas dopamine, GABA, and glutamate are three key
neurotransmitter systems implicated in the pathophys-
iology of schizophrenia, alterations in other neurotrans-
mitter systems have been suggested and include seroto-
nin (Abi-Dargham, 2007), acetylcholine (Sarter et al.,
2005) [muscarinic receptors (Raedler et al., 2007; Lang-
mead et al., 2008) and nicotinic receptors (Woodruff-Pak
and Gould, 2002; Levin and Rezvani, 2007)], norepi-
nephrine (Friedman et al., 1999; Yamamoto and
Hornykiewicz, 2004), and numerous neuropeptides
[neuropeptide Y (Eaton et al., 2007), tachykinins (Chahl,
2006), neurotensin (Ca´ceda et al., 2006), and orexins/
hypocretins (Deutch and Bubser, 2007)].
5. Intracellular Signaling Cascades. As mentioned
in section II.A, metabotropic receptors involve coupling
to various G-proteins, leading to the regulation of cAMP
and IP3 second messengers and subsequent downstream
signaling systems including kinase cascades and tran-
scriptional factors. One key regulatory aspect of the
kinase signaling cascades is protein phosphorylation,
with protein kinases resulting in phosphorylation of pro-
teins, which alters their regulation and downstream
effects, and protein phosphatases reversing the phos-
phorylation reactions providing for finely tuned regula-
tion. As a model, we will briefly review the intracellular
signaling underlying the actions of dopamine (for re-
view, see Girault and Greengard, 2004; Beaulieu et al.,
2005, 2007). However, many metabotropic receptors and
even iontropic receptors can interact with these and
other effector molecules. There is evidence for dysregu-
lation within these signaling cascades in patients with
schizophrenia.
As reviewed by Beaulieu et al. (2007), the stimulation
of dopamine receptors leads to a conformation change in
the receptor and activation of G-proteins that either
activate or inhibit adenylyl cyclase, thereby modulating
the activity of cAMP-dependent protein kinase (PK) A.
The D1 class receptors activate adenylyl cyclase,
whereas the D2 class receptors inhibit adenylyl cyclase.
PKA phosphorylates a number of downstream protein
targets including DARPP-32, cAMP-response element-
binding protein (CREB), and extracellular signal-regu-
lated kinase (ERK). This initial wave of responses re-
flects G-protein-mediated signaling and is thought to be
relatively rapid and transient in nature. After stimula-
tion, dopamine receptors are phosphorylated by G-pro-
tein-coupled receptor kinases and -arrestins are re-
cruited, leading to termination of G-protein-dependent
signaling and internalization of the receptor (desensiti-
zation). In addition, the D2 class receptors are associated
with cAMP-independent signaling involving formation
of a signaling complex comprising -arrestin 2, protein
phosphatase 2A, and Akt (protein kinase B). The forma-
tion of this signaling complex leads to inactivation of Akt
by protein phosphatase 2A, and subsequent activation of
glycogen synthase kinase-3 (GSK-3)-mediated signaling.
This second wave reflects -arrestin 2-mediated signal-
ing and is thought to be a more progressive and longer-
lasting response. These signaling cascades control pro-
tein phosphorylation, resulting in the regulation of
ligand- and voltage-gated ion channels, as well as pro-
duction of transcription factors that regulate the subse-
quent expression of specific genes.
In addition to adenylyl cyclase regulation, several
neurotransmitter receptors interact with G-proteins to
regulate PLC and subsequent signaling via IP3 and in-
tracellular Ca2 release and diacylglycerol. IP3 interacts
with receptors on the endoplasmic reticulum, leading to
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increased Ca2 levels within the cytosol and increased
Ca2 signaling. Diacylglycerol activates protein kinase
C, leading to the phosphorylation of a number of pro-
teins. Whereas dopamine receptors and the GABAB re-
ceptor (Bowery, 2006) regulate adenylyl cyclase, select
metabotropic receptors within the other neurotransmit-
ter systems interact with both signaling cascades: glu-
tamatergic receptors (AC: mGlu2–4,6–8; PLC: mGlu1,5)
(Gerber et al., 2007, Moghaddam, 2004), muscarinic ace-
tylcholine (ACh) receptors (AC: M2,4; PLC: M1,3,5) (Rae-
dler et al., 2007; Langmead et al., 2008), 5-HT receptors
(AC: 5-HT1A,B,D,4,5A,B,6,7; PLC: 5-HT2A,B,C) (Barnes and
Sharp, 1999; Hoyer et al., 2002), and adrenergic recep-
tors (PLC: 1,2; AC: 1,2) (Ramos and Arnsten, 2007).
Regulators of G-protein signaling (RGS4) (28 RGS
proteins) function as GTPase-activator proteins for het-
eromeric G-protein  (G) subunits and accelerate the
hydrolysis of G-bound GTP, shortening the duration of
intracellular G-protein-coupled receptor signaling and
thereby modulating the intracellular effects of G-pro-
tein-coupled neurotransmitters (for review, see Lang et
al., 2007). RGS4 mRNA levels were significantly lower
in postmortem samples of the dorsolateral prefrontal
cortex of subjects with schizophrenia compared with
those of matched control subjects (Mirnics et al., 2001b).
RGS9-2 expression was reduced in schizophrenia hip-
pocampi compared with control tissue and in amphet-
amine-sensitized rat striatum as an animal model of
schizophrenia (Seeman et al., 2007).
DARPP-32 is a key regulator of kinase phosphatase
signaling cascades and is modulated by dopaminergic,
serotonergic, and glutamateric neurotransmission
(Svenningsson et al., 2003). DARPP-32 can be phosphor-
ylated at four distinct sites, the location of phosphoryla-
tion influencing its function as an amplifier or inhibitor
of PKA (or PKG)-mediated signaling. A significant re-
duction in DARPP-32 expression has been observed
postmortem in the dorsolateral prefrontal cortex of pa-
tients with schizophrenia (Albert et al., 2002).
Akt is a serine/threonine protein kinase regulated by
both G-protein-coupled receptors (GPCRs) and a number
of neurotrophic receptors. Akt is involved in a range of
diverse cellular processes including neuronal cell prolif-
eration, survival, apoptosis, differentiation, neurotro-
phin secretion, and synaptic plasticity (Dudek et al.,
1997; Lawlor and Alessi, 2001; Ciani et al., 2002; Brazil
et al., 2004; Sweatt, 2004). Akt is modulated by phos-
phorylation at different residues after dopamine recep-
tor activation or NMDA receptor potentiation (for re-
view, see Lei et al., 2008). GSK-3 is constitutively
active and is involved in a number of diverse functions
including glycogen synthesis, cell growth and differenti-
ation, amyloid  metabolism, and phosphorylation of tau
(Gould and Manji, 2005).
GSK-3 is a central component of the developmentally
important wingless signaling and insulin signaling
pathways, and both pathways have been implicated in
schizophrenia (for review, see Lovestone et al., 2007).
Akt-GSK-3 signaling has also been implicated in PCP-
induced neurodegeneration (Lei et al., 2008). Of interest,
heightened GSK-3 activity is proapoptotic via activa-
tion of the Bcl-2 family member BAX. Akt is the princi-
pal kinase to phosphorylate and inhibit GSK-3 activity,
a regulatory pathway that may facilitate neuronal sur-
vival. A decrease in AKT1 protein levels and decreased
phosphorylation of GSK-3 at Ser-9 were observed in
peripheral lymphocytes and postmortem brain tissue
from patients with schizophrenia, suggestive of a pro-
apoptotic state (Emamian et al., 2004). Emamian et al.
(2004) and others (Bajestan et al., 2006; Kalkman, 2006)
have implicated the Akt1 gene as a potential suscepti-
bility gene for schizophrenia. Likewise, Zhao et al.
(2006) reported decreases in Akt content and activity in
the dorsolateral prefrontal cortex that were accompa-
nied by an elevated content of GSK-3 and GSK-3 but
without changes in phospho-Ser(21/9) GSK-3/ levels
in postmortem tissue of medicated patients with schizo-
phrenia (relative to those of control patients).
In contrast, others have observed a reduction in
GSK-3 protein levels and GSK-3 activity in frontal
cortex (Kozlovsky et al., 2000, 2001) and decreased
GSK-3 mRNA in postmortem dorsolateral prefrontal
cortex of patients with schizophrenia compared with
that of patients with bipolar and unipolar disorders and
healthy control subjects (Kozlovsky et al., 2004). Reduc-
tions in GSK-3 may result in an imbalance in the rate
and timing of apoptosis during neurodevelopment (Ko-
zlovsky et al., 2004).
Mitogen-activated protein (MAP) kinases are a family
of serine/threonine kinases that regulate neuronal sur-
vival, differentiation, and plasticity and are activated
after ligand binding to NMDA, muscarinic, acetylcho-
line, serotonin, and dopamine receptors (for review, see
Schaeffer and Weber, 1999; Einat et al., 2003; Kyosseva,
2004). MAP kinases include ERK1 and ERK2, c-Jun
NH2-terminal kinase/stress-activated protein kinase,
and p38 MAP kinase. When activated, the MAP kinases
are translocated to the nucleus and activate transcrip-
tion of immediate early genes c-fos and c-jun, leading to
increased translation of the Fos and Jun families of
proteins, which heterodimerize to form the activator
protein-1 complex that controls subsequent transcrip-
tion of neuronal genes encoding neuropeptides and neu-
rotransmitter receptors (for review, see Kyosseva, 2004).
Increased expression of several intermediates of the
ERK cascade and downstream transcript targets was
observed in the cerebellar vermis of patients with schizo-
phrenia (Kyosseva et al., 1999). In addition, selective
increases in ERK2, c-fos, and c-jun protein and mRNA
levels were observed within the thalamus of patients
with schizophrenia relative to levels in control subjects
(Kyosseva, 2004). Finally, given the pervasiveness of
Ca2 signaling motifs, it has been argued that many of
the changes observed in schizophrenia may be associ-
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ated with dysfunction in calcium signaling (Lidow,
2003).
In summary, schizophrenia has been associated with
dysfunction in many neurotransmitter systems and at
many different levels. The current view emphasizes
NMDA receptor hypofunction as an underlying mecha-
nism that may lead to both reduced GABAergic tone and
increased dopaminergic tone. However, this basic tenet
rests upon a plethora of molecular changes that have
been observed across many brain pathways, for which
there exists an intricate balance of interactions among
several of the neurotransmitter systems. In addition,
differences in gene expression and the experience of
environmental “insults” may underlie the variability
that is seen in the risk of developing this mental illness.
B. Neuroanatomical Pathology
Numerous studies have documented the presence of
structural changes in the brains of patients with schizo-
phrenia including loss of cortical volume (gray matter
and white matter), increased ventricular volume, in-
creased neuronal density, reduction of neuropil, damage
to myelinated fiber tracts (white matter), and alter-
ations in the number and distribution of supporting glia.
Collectively, these changes reflect alterations in the
structure and connections of neurons, a finding that
underscores disruption in the communication between
brain regions.
A large number of studies have suggested that there is
a loss of cortical volume in schizophrenia, particularly in
prefrontal and temporal cortical areas (for review, see
Harrison, 1999; Convit et al., 2001; Narr et al., 2005,
Steen et al., 2006). Despite a decrease in the volume of
the prefrontal cortex (PFC) in schizophrenia, a signifi-
cant decrease in neuronal number has not been found,
giving rise to the “reduced neuropil hypothesis”
(Selemon and Goldman-Rakic, 1999). Postmortem stud-
ies suggest that decreases in axon terminals, pretermi-
nals (presynaptic elements), and dendrites, albeit to
varying degrees, contribute to the loss of cortical volume
(Harrison, 1999; Glantz and Lewis, 2000; Mirnics et al.,
2001a). However, these observations do not preclude the
loss of selective groups of neurons, and several studies
have described reduced numbers of neurons in several
cortical and subcortical regions and within specific neu-
rochemically defined neuronal cell groups (for review,
see Pe´rez-Neri et al., 2006). Longitudinal studies have
suggested that there is progressive volume loss in first-
episode schizophrenia (Steen et al., 2006) in several
cortical regions /DeLisi et al., 1997), total cerebral gray
matter (Cahn et al., 2002), frontal cortex (Gur et al.,
1998), and superior temporal gyrus (Kasai et al., 2003).
As a corollary, there is evidence for increased ventricle
volume in patients with schizophrenia during the course
of the disease and/or during a psychotic episode (DeLisi
et al., 1997; Nair et al., 1997; Rapoport et al., 1997;
Davis et al., 1998; Lieberman et al., 2001b; Mathalon et
al., 2001).
Although the majority of studies have reported de-
creases in cortical gray matter volume, an increase in
the volume of the caudate nucleus has been observed in
patients with schizophrenia. Caudate hypertrophy, ear-
lier thought to be a pathological feature of schizophrenia
(Heckers et al., 1991; Swayze et al., 1992), has more
recently been shown to be a side effect of antipsychotic
treatment (Chakos et al., 1994; Hokama et al., 1995).
Several lines of evidence suggest a compromise in the
integrity of white matter tracts providing anatomical
and functional connections between brain regions (for
review, see Davis et al., 2003, Walterfang et al., 2006).
Decreased global white matter volume has been ob-
served in patients with schizophrenia (Cannon et al.,
1998; Wright et al., 2000), with reductions revealed in
comparison with both unaffected siblings and healthy
control subjects (Cannon et al., 1998), an important find-
ing as white matter volumes also decrease with age in
healthy individuals (Bartzokis et al., 2001). Volume re-
ductions have also been observed specifically within the
white matter of the PFC (Breier et al., 1992; Buchanan
et al., 1998; Sanfilipo et al., 2000; Sigmundsson et al.,
2001), frontal cortex (Ho et al., 2003), temporal cortex
(Okugawa et al., 2002; Mitelman et al., 2003), and pari-
etal and occipital cortices (Milev et al., 2003; Mitelman
et al., 2003). In some studies, a reduction in white mat-
ter volume has been associated with negative symptoms
(Sanfilipo et al., 2000; Sigmundsson et al., 2001; Ho et
al., 2003). Numerous studies provide evidence of focal
damage occurring and accumulating along white matter
tracts within the brains of patients with schizophrenia,
including white matter hyperintensities, reductions in
myelin or axonal membrane integrity, and decreased
anisotrophy (or decreased coherence) within white mat-
ter (for details, see Davis et al., 2003; Walterfang et al.,
2006).
Again, although the majority of studies indicate de-
creases in white matter volume in patients with schizo-
phrenia, at least one study has reported an increase in
white matter in the temporal lobes in childhood-onset
schizophrenia (Taylor et al., 2005). Recently, Federspiel
et al. (2006) found evidence for both reduced and ele-
vated anisotrophy (connectivity in white matter bun-
dles) in patients with schizophrenia compared with that
in control subjects. Increases in white matter volume
have been observed during exacerbation of psychosis
with decreases occurring upon symptom remission
(Christensen et al., 2004), and increased anisotrophy
has been reported in hallucinating patients compared
with control subjects and patients without hallucina-
tions (Hubl et al., 2004). These disparate findings as a
whole may point to dynamic changes taking place within
the brain wherein increases in white matter volume
might reflect active processes of disease (i.e., swelling of
myelin, necrosis and apoptosis of oligodendroglia, or re-
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modeling of connections associated with psychosis) or
possibly compensatory, restorative changes, whereas
loss of white matter might reflect a more refractory
state.
At the cellular level, morphological abnormalities and
density changes have been observed in neurons and in
glia, including the oligodendroglia, which provide and
maintain the myelin sheath surrounding neuronal ax-
ons (for review, see Walterfang et al., 2006). Among the
most intriguing of the pathological features of schizo-
phrenia is a decrease in dendritic spine density in PFC
neurons. Postmortem studies have shown a decrease in
basal dendritic spine density of layer III and V pyrami-
dal cells in the PFC (Garey et al., 1998; Glantz and
Lewis, 2000; Kalus et al., 2000; Broadbelt et al., 2002;
Black et al., 2004; Kolluri et al., 2005). Because the
dendritic spines of pyramidal cells receive inputs from
DA axons (Sesack et al., 2003) and DA receptors are
expressed on spines, it is possible that changes in DA
transmission may lead to structural changes in the den-
drites of PFC pyramidal cells. Specifically, because DA
axons synapse predominantly on spine necks, with an
excitatory input synapsing with spine heads (Sesack et
al., 2003), a loss of cortical DA would be predicted to
decrease the capacity of pyramidal cells to gate excita-
tory input onto dendritic spines, which in turn would
lead to hyperexcitability of the cell and a (slow) excito-
toxic process. This seems to be the case in striatal me-
dium spiny neurons, which share with cortical pyrami-
dal cells the triadic arrangement of DA axons
terminating on the spine neck and a corticostriatal glu-
tamatergic axon that synapses onto the spine head.
Thus, medium spiny neurons in the striatum of animals
with lesions of the nigrostriatal DA neurons or humans
with Parkinson’s disease have a decrease in overall den-
dritic length and spine density (Zaja-Milatovic et al.,
2005).
Following this reasoning, Wang and Deutch (2008)
recently examined the effects of lesions disrupting the
DA innervation of the PFC on pyramidal cells. They
found that layer V pyramidal cells had a decrease in
total dendritic length, dendritic spine density, and den-
dritic complexity (branching). Thus, DA denervation of
the PFC resulted in dystrophic changes of pyramidal cell
dendrites in the PFC, recapitulating a key pathological
feature of schizophrenia (Glantz and Lewis, 2000).
In summary, many studies have shown neuropatho-
logical changes within the brains of patients with schizo-
phrenia. Altered brain structure and function are evi-
dent during the first episode of schizophrenia, and there
is evidence (at least for some patients) of progressive loss
of tissue volume and cellular elements over time. Sev-
eral of the changes seem to reflect active states of psy-
chosis, illustrating the dynamic state of morphological
changes occurring within the brain and the potential for
compensatory changes to occur at least early in the
stages of the illness.
C. Apoptosis and N-Methyl-D-aspartate Antagonist-
Induced Neurodegeneration
As noted in the preceding section, the cortical neuro-
pathology observed in schizophrenia predominantly in-
cludes neuronal atrophy, decreased neuropil, and alter-
ations in neuronal density suggesting that the
connections between neurons, synaptic circuitry, is al-
tered. Dysregulation of neuronal apoptosis has been im-
plicated in the pathophysiology of schizophrenia, and
most recently sublethal apoptotic activity has been pro-
posed, resulting in the loss of synapses without cell
death (for review, see Jarskog et al., 2005; Glantz et al.,
2006).
Apoptosis or programmed cell death is a process nor-
mally associated with the elimination of redundant neu-
rons during neurodevelopment (Johnson et al., 1995).
Apoptosis involves the regulation of a complex molecular
cascade controlling the activation of a family of cysteine
proteases known as caspase proteins (for review, see
Glantz et al., 2006). Caspases are responsible for break-
ing down important structural and functional proteins,
leading to cellular degradation and eventually death.
Apoptosis results from a cascade of gene activation and
involves genes that both promote (i.e., Bax) (Schlesinger
et al., 1997; Gross et al., 1998) and oppose the process
(i.e., Bcl-2) (Craig, 1995; Schlesinger et al., 1997; Adams
and Cory, 1998).
Although widespread neuronal loss is not observed
within the brains of patients with schizophrenia, the
anterior cingulate cortex is one area in which layer-
specific reductions in subtypes of neurons have been
identified (Benes et al., 1991, 2001). Using the Klenow
method to identify apoptotic-positive neurons, subjects
with chronic schizophrenia actually demonstrated a de-
crease in a distinct subset of Klenow-positive neurons
compared with that in matched control subjects and
subjects with bipolar disorder (Benes et al., 2003). Benes
et al. suggested that the reduction in apoptotic-positive
neurons represented either a compensatory down-reg-
ulation to promote cell survival or a failure to mount
an appropriate apoptotic response to an oxidative
challenge.
Caspase activity has also been localized to dendrites,
dendritic spines, and axonal terminals (Yan et al., 2001),
and synaptic apoptotic activity has been implicated in
adaptive plasticity and neurodegenerative disorders
(Mattson and Duan, 1999). Two reports have described
alterations in apoptotic regulatory proteins in patients
with schizophrenia. In one study, a 50% increase in the
Bax/Bcl-2 ratio was observed in the temporal cortex of
patients with schizophrenia compared with the ratio in
matched control subjects (Jarskog et al., 2004). An ele-
vated ratio of proapoptotic (i.e., Bax) to antiapoptotic
(e.g., Bcl-2) protein levels may up-regulate cytochrome c
release from mitochondria and subsequent caspase acti-
vation [for review (Glantz et al., 2006). In a second
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study, Bcl-2 levels were reported to be 30% lower in the
temporal cortex in patients with schizophrenia than in
control subjects (Jarskog et al., 2000). Bcl-2 levels can
exert neuroprotective and neurotrophic effects, and the
lower levels suggest less neuroprotection.
A vast array of stimuli can activate apoptosis in neu-
rons (Sastry and Rao, 2000). Many of these stimuli have
been implicated in the pathophysiology of schizophrenia
including glutamate excitotoxicity, increased calcium
flux, mitochondria dysfunction, oxidative stress, and de-
creased neurotrophic levels. Given the importance of
NMDA receptor hypofunction to schizophrenia, it is im-
portant to note that the administration of NMDA antag-
onists is associated with apoptotic neurodegeneration.
Early work identified vacuolated neurons as injured or
dying neurons within posterior cingulate and retrosple-
nial cortices after the administration of NMDA antago-
nists, with additional regions being affected, depending
on dose and duration of exposure (Farber et al., 1995).
Subsequent work demonstrated NMDA antagonist-in-
duced apoptotic neurons via electron microscopy or ter-
minal dUTP nick-end labeling (Johnson et al., 1998) or
silver staining (Griffiths et al., 2000). The mechanism of
NMDA antagonist (PCP)-induced apoptosis was shown
to involve increased expression of Bax and decreased
expression of Bcl-XL, with a decrease in the Bcl-XL/Bax
ratio that could be prevented by the addition of super-
oxide dismutase or catalase (Wang et al., 2000). Addi-
tional studies have supported and extended these initial
findings (Wang et al., 2003, 2004a, 2005a, 2008; Wang
and Johnson, 2005). Recent studies have demon-
strated a role for caspase-3 (Wang and Johnson, 2007)
and Akt-GSK-3 signaling (Lei et al., 2008) in PCP-
induced neurodegeneration.
In summary, schizophrenia is not associated with
widespread neuronal cell loss but rather with a selective
reduction in the number of specific cell types, as well as
changes in the morphology of neurons including reduc-
tions in dendritic length and spine density. Apoptotic
mechanisms may underlie both the loss of specific
groups of neurons and changes in neuronal morphology.
Of interest, in some instances, there is evidence for
reduced apoptotic activity. Given that schizophrenia re-
flects impaired information processing, an inability to
reduce neuronal number and/or connections seen nor-
mally in development may be as relevant to schizophre-
nia as a reduction in dendritic processes and spine den-
sity or loss of specific cell groups.
D. Altered Levels of Neuroactive Steroids
Neuroactive steroids are endogenous neuromodula-
tors synthesized either within the brain (neurosteroids)
or in the periphery by the adrenal glands and gonads.
Neuroactive steroids can alter neuronal excitability via
nongenomic effects by acting at inhibitory GABAA recep-
tors and/or excitatory NMDA receptors, among others
(for review, see Paul and Purdy, 1992; Belelli and Lam-
bert, 2005). There is also evidence for a potential role of
these neurosteroids in controlling GABA and glutamate
release. Neuroactive steroids/neurosteroids have also
been implicated in neuroprotection, myelination, and
modulation of the stress response (for review, see Marx
et al., 2006b).
A number of neuroactive steroids are present in hu-
man postmortem brain at physiologically relevant nano-
molar concentrations (Marx et al., 2006b) and serve as
allosteric modulators of the GABAA receptor. Allopreg-
nanolone (ALLO) potentiates the GABAA receptor re-
sponse more potently than benzodiazepines or barbitu-
rates (Majewska et al., 1986; Morrow et al., 1987, 1990).
ALLO levels are lower in postmortem brain tissue from
parietal cortex in subjects with schizophrenia, suggest-
ing that an ALLO deficit is potentially present in this
disorder (Marx et al., 2006b).
Pregnenolone sulfate and dehydroepiandrosterone
(DHEA) are positive modulators of NMDA receptors
(Wu et al., 1991; Irwin et al., 1994; Bergeron et al., 1996;
Debonnel et al., 1996; Compagnone and Mellon, 1998)
and negative modulators of GABAA receptors (Majewska
et al., 1988, 1990; Imamura and Prasad, 1998; Park-
Chung et al., 1999). Pregnenolone and DHEA levels are
elevated postmortem in subjects with schizophrenia in
the posterior cingulate and parietal cortex compared
with levels in control subjects (Marx et al., 2006b).
A number of studies have reported altered levels of
neuroactive steroids in patients with schizophrenia (for
review, see Shulman and Tibbo, 2005), although varia-
tions in the results observed clearly exist. Recent find-
ings have described significant elevations of plasma lev-
els of DHEA in patients with schizophrenia compared
with control subjects regardless of gender (di Michele et
al., 2005). There is evidence that DHEA can improve
some of the symptoms of schizophrenia (Strauss et al.,
1952; Strous et al., 2003).
In summary, given the complexity of the regulation of
neuroactive steroids and neurosteroids and the range of
changes observed in patients with schizophrenia, it is
difficult to assimilate all of the current information into
a single, explanatory model. Given that both preg-
nenolone sulfate and DHEA are positive modulators of
excitatory NMDA receptors and allopregnanolone is a
positive modulator of inhibitory GABAA receptors, the
neuroactive steroid milieu in subjects with schizophre-
nia may reflect a net increase in neuronal excitation
(Marx et al., 2006b). Alternatively, the NMDA receptor
hypofunction theory of schizophrenia suggests that ele-
vations in pregnenolone and DHEA may be beneficial
(Shulman and Tibbo, 2005), which is consistent with
some of these data.
E. Decreased Mitochondrial Function
Mitochondrial insufficiency during brain development
has been suggested as a cause of reduced synaptic plas-
ticity that eventually contributes to the pathogenesis of
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schizophrenia (Ben-Shachar and Laifenfeld, 2004). Im-
pairment of oxidative energy metabolism has been
shown to potentiate NMDA receptor-mediated excitotox-
icity, and it has been proposed that decreases in ATP
synthesis can impair the function of the Na/K-AT-
Pase pump (Simpson and Isacson, 1993; Weller and
Paul, 1993; Greene and Greenamyre, 1995), thereby de-
creasing plasma membrane potential, relieving the volt-
age-dependent Mg2 blockade of NMDA-receptor, and
resulting in hypersensitivity to glutamate (Greene and
Greenamyre, 1996). Several independent lines of evi-
dence support a role for mitochondrial insufficiency in
the pathogenesis of schizophrenia.
Brain imaging studies have revealed decreased en-
ergy metabolism in the frontal lobes of patients with
schizophrenia compared with that in healthy control
subjects (for review, see Ben-Shachar and Laifenfeld,
2004). Analysis of mitochondrial respiratory enzymes in
postmortem brain samples indicates a decrease in the
activity of respiratory complex IV (cytochrome c oxidase)
in the frontal cortex and temporal cortex and a decrease
in activity of respiratory enzyme complexes I and III in
the temporal cortex and basal ganglia of patients with
schizophrenia compared with that in healthy control
subjects (Maurer et al., 2001). A reduction in the number
of mitochondria throughout the neuropil in both the
caudate and putamen of postmortem samples of patients
with schizophrenia versus control subjects has also been
observed (Kung and Roberts, 1999).
More recently, altered gene expression of mitochon-
drial proteins has been demonstrated in patients with
schizophrenia, including a reduction in mRNA and pro-
tein levels of the 24- and 51-kDa subunits of complex I in
the prefrontal cortex, consistent with diminished respi-
ratory capacity (Karry et al., 2004). More extensive pro-
teomic analysis has revealed that nearly half of all pro-
tein differences detected between patients with
schizophrenia and healthy control subjects are associ-
ated with mitochondrial function and oxidative stress
(Prabakaran et al., 2004). Large-scale DNA microarray
analysis of postmortem brains of patients with schizo-
phrenia has demonstrated a global down-regulation of
mitochondrial genes, although medication effects could
not be ruled out (Iwamoto et al., 2005).
In summary, mitochondrial functioning is essential
for normal brain development and the maintenance of
normal brain function. Evidence has shown impaired
mitochondrial functioning within the brains of patients
with schizophrenia. Possible links between impaired mi-
tochondrial functioning and glutamate-induced neuro-
toxicity have been proposed.
F. Dysfunction of Glucose Metabolism
The notion of a possible relationship between glu-
cose metabolism and psychiatric illness is more than
100 years old and was first articulated by Maudsley
who observed that diabetes and insanity are often
coexpressed in families (as quoted by Mukherjee et al.,
1989). Insulin-shock therapy was subsequently shown
to be successful in treating some patients with long-
standing psychosis (Sakel, 1994). Since these early
observations, evidence has accumulated to support a
relationship between glucose metabolism dysfunction
and schizophrenia.
Ben-Shachar (2002), Karry et al. (2004), and Maurer
et al. (2001) have reported generalized mitochondrial
(energy) dysfunction in schizophrenia, whereas Blass
(2002) has emphasized a more selective defect in glucose
metabolism as a contributory factor in psychosis. These
findings are consistent with the hypofrontality or de-
creased cerebral blood flow and glucose metabolic rate in
the frontal cortex of patients with untreated schizophre-
nia detected in most brain imaging studies (Ingvar and
Franze´n, 1974; Wolkin et al., 1985; Weinberger et al.,
1986; Buchsbaum et al., 1990; Andreasen et al., 1992),
but not all (Mathew et al., 1982; Gur et al., 1987). More-
over, lower rates of glucose metabolism (especially in
prefrontal areas) are correlated with negative symptoms
(Andreasen et al., 1992) and poorer cognitive perfor-
mance (Weinberger et al., 1986; Buchsbaum et al., 1990)
in patients with schizophrenia.
Glucose is the required energetic fuel for the mamma-
lian brain, with glucose transporter (GLUT) proteins
delivering glucose from the circulation to the brain:
GLUT1 found in the microvascular endothelial cells of
the blood-brain barrier and glia and GLUT3 found in
neurons (for review, see Simpson et al., 2007). Lactate is
the glycolytic product of glucose metabolism and is
transported into and out of neural cells by monocarboxy-
late transporters (MCTs): MCT1 in the blood-brain bar-
rier and astrocytes and MCT2 in neurons. McDermott
and de Silva (2005) postulated that impaired neuronal
glucose uptake via GLUT 1 and GLUT 3 may explain the
imaging, postmortem, and pharmacological findings in
schizophrenia. They have suggested that reduced glu-
cose availability in situations of high demand may pro-
duce acute symptoms of misperceptions, misinterpreta-
tions, anxiety, and irritability that are features similar
to those seen in prodromal and first-onset schizophre-
nia. In addition, reduced glucose uptake would reduce
the production of glutamate, resulting in a state func-
tionally similar to those produced by NMDA antago-
nists. It is also possible that abnormalities in insulin
signaling may contribute to deficiencies in glucose me-
tabolism in neurons and limit optimal brain develop-
ment and brain function (Bondy and Cheng, 2002).
In summary, decreased cerebral blood flow and glu-
cose metabolic rate in the frontal cortex of patients with
untreated schizophrenia have been detected in most
brain imaging studies. Lower rates of glucose metabo-
lism have been correlated with negative symptoms and
poorer cognitive performance. And it has been postu-
lated that reduced availability of glucose via fewer glu-
cose transporters or decreased functional capacity could
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explain the imaging, postmortem and pharmacological
findings reported in schizophrenia, although supporting
data for this theory are needed. Dwyer et al. (2003b)
have suggested that it may be possible to improve func-
tional activity in patients with schizophrenia by enhanc-
ing glucose metabolism and related signaling pathways
(e.g., insulin-like growth factor and Akt/protein ki-
nase B) in the brain with small-molecule drugs. Girgis
et al. (2008) suggested that this may be a mechanism
by which clozapine-like SGAs exert their therapeutic
effects.
G. Elevated Levels of Oxidative Stress
Oxidative stress occurs when there is dysequilibrium
between prooxidant and antioxidant processes in favor
of the former and generally occurs as a consequence of
increased production of free radicals when the antioxi-
dant defense system is inefficient or as a combination of
both events. Free radicals (superoxide radical, hydrogen
peroxide, and hydroxyl anion) are formed during many
biochemical reactions involving oxygen including the
mitochondrial respiratory process. These reactive oxy-
gen species are generally kept in check by an antioxi-
dant defense system comprising a series of enzymatic
[superoxide dismutase (SOD), catalase, and glutathione
peroxidase] and nonenzymatic [glutathione, -tocoph-
erol (vitamin E), ascorbic acid (vitamin C), and -caro-
tene] components (for review, see Reddy and Yao, 1996).
Oxidative stress can initiate a number of pathophysio-
logical processes, leading to cellular toxicity and is a
mechanism that is common to many neurodegenerative
diseases (Reddy and Yao, 1996).
A number of studies provided evidence for an eleva-
tion in oxidative stress and a reduction in antioxidant
capacity in patients with schizophrenia. Markers of lipid
peroxidation, thiobarbituric acid reactive species and
malondialdehyde, are elevated in patients with schizo-
phrenia (Dietrich-Muszalska et al., 2005; Zhang et al.,
2006). An increase in the oxidative metabolites of bili-
rubin (i.e., biopyrrins) has been observed in urine of
patients with schizophrenia (Miyaoka et al., 2005). Post-
mortem studies have provided evidence for oxidative
DNA damage in the hippocampus of elderly patients
with schizophrenia (Nishioka and Arnold, 2004) and for
elevated levels of nitric oxide in brains of patients with
schizophrenia (Yao et al., 2004). In addition, there is
evidence for lower levels of antioxidants and/or antioxi-
dant activity in patients with schizophrenia (Ranjekar
et al., 2003; Dietrich-Muszalska et al., 2005; Yao et al.,
2006; Zhang et al., 2006).
Because lower antioxidant enzyme activity has been
observed in patients with schizophrenia, it has been
proposed that oxidative stress-mediated cell damage
may underlie development of schizophrenia (Ranjekar et
al., 2003). However, some studies have actually reported
increased levels of antioxidants and/or antioxidant en-
zymes in patients with schizophrenia (Zhang et al.,
2003; Michel et al., 2004). This latter finding might
suggest the presence of a compensatory process designed
to maintain homeostasis (Michel et al., 2004), whereby
up-regulation of some antioxidants such as SOD may
occur in response to and coincide with elevations in
oxidative stress.
In summary, markers of oxidative stress are ele-
vated in schizophrenia, and there is evidence for both
up- and down-regulation of antioxidants and/or anti-
oxidant enzymes. Similar to changes occurring in neu-
rotransmitter regulation and neuronal morphology,
the brain may try to compensate for ongoing neurode-
generative changes (i.e., increased oxidative stress).
The increases in oxidative stress parameters may re-
flect changes co-occurring in other systems such as
free radical production that occurs in mitochondria
during oxidative phosphorylation.
H. Reduced Neurotrophic Factor Expression
Neurotrophic factors are critical for normal brain de-
velopment and maintenance throughout the life of the
organism (Levi-Montalcini, 1987; Barde, 1994; Dono,
2003; Rosenstein and Krum, 2004). The neurotrophic
factors include nerve growth factor (NGF), brain-derived
neurotrophic factor (BDNF), basic fibroblast growth fac-
tor (FGF), neurotrophin-3 (NT-3), epidermal growth fac-
tor, and vascular endothelial growth factor. Their role
has generally been to enhance neuroplasticity (i.e., reg-
ulation of apoptosis and increased cell survival) and to
promote regrowth (dendritic sprouting and synaptogen-
esis) and new growth (neurogenesis) (Thoenen, 1995;
Cameron et al., 1998; Sofroniew et al., 2001; Sun et al.,
2003; Radecki et al., 2005). Because abnormal neurode-
velopment and a variety of pathophysiological processes
after the onset of symptoms are considered to contribute
to the complex neuropathophysiology of schizophrenia,
neurotrophic factors may play a pivotal role in improved
neuroplasticity and thereby long-term clinical outcome.
Altered expression of neurotrophic factors has been
implicated in the neuropathophysiology of schizophrenia
and bipolar disorders (Shoval and Weizman, 2005; Buck-
ley et al., 2007a). In postmortem brain tissue from pa-
tients with schizophrenia, a significant increase in
BDNF concentrations and a decrease in NT-3 concentra-
tions were observed in cortical areas and a significant
decrease of BDNF levels was observed in the hippocam-
pus (Durany et al., 2001). Significant reductions in
BDNF levels have been reported in the serum of patients
with chronic schizophrenia (Toyooka et al., 2002; Tan et
al., 2005) and in drug-naive, first-episode psychotic pa-
tients (Buckley et al., 2007b). Pillai et al. (2007) also
reported significant reductions of BDNF levels in the
plasma and cerebrospinal fluid CSF of drug-naive, first-
episode patients. Likewise, significant reductions in
plasma NGF have been observed in never-medicated,
first-episode psychotic patients and in chronically med-
icated patients with schizophrenia (Parikh et al., 2003).
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In summary, neurotrophic factors play an important
role in neuroplasticity, promotion of regrowth and new
growth, and the general resilience of cells. The majority
of findings have demonstrated a reduction in neurotro-
phic factors BDNF, NT-3, and NGF. These observations
suggest that the brains of patients with schizophrenia
may be disadvantaged in their ability to maintain ade-
quate connections between neurons, to effectively con-
trol programmed cell death and cell proliferation, and to
adapt to changes in their environment and defend
against various physiological insults.
III. Comparison of Antipsychotic Drugs in
Animal Models of Antipsychotic Efficacy,
Neurotransmitter Regulation, and
Neuroprotection
A. Traditional Animal Models of Antipsychotic Activity
All marketed APDs to date fundamentally share some
degree of interaction with DA D2 receptors acting either
as DA antagonists or as weak partial agonists (as in the
case of aripiprazole). The clinical effects of APDs are
well correlated with DA D2 receptor affinity in binding
assays (Seeman et al., 1976; Creese et al., 1996). How-
ever, most SGAs have been shown to have lower affinity
for DA D2 receptors in binding assays than FGAs and to
have high affinity for 5-HT2A receptors relative to DA D2
receptor affinity (Meltzer et al., 1989; Bymaster et al.,
1996; Schotte et al., 1996). Both lower affinity for DA D2
receptors and higher affinity for 5-HT2A receptors have
been proposed to contribute to the novel profile of the
SGAs (Meltzer et al., 1989; Kapur and Seeman, 2001).
Particular SGAs also may have affinity for a number of
other neuronal receptors possibly including -adrener-
gic, histamine H1, serotonergic receptors other than
5-HT2A, and muscarinic receptors, and this may affect
their efficacy and side effect profile (Bymaster et al.,
1996; Schotte et al., 1996). Thus, in vitro binding assays
have demonstrated that SGAs have a different and more
variable receptor binding profile than FGAs.
Traditional animal models of schizophrenia have fo-
cused on finding drugs that selectively block limbic DA
D2 receptors. Models include dopaminomimetic-induced
motor hyperactivity, conditioned avoidance behavior,
electrophysiological, brain regional selectivity, neuro-
chemical, and neuroendocrine paradigms. Drug-induced
catalepsy (freezing behaviors), which is the animal ho-
molog of EPS, is often evaluated to determine the poten-
tial for this adverse event. We highlight the comparative
effects of FGAs and SGAs in these models.
1. Dopamine Stimulant-Induced Hyperactivity. A
widely used screening test for in vivo DA D2 antagonist
activity is blockade of DA stimulant-induced (i.e., d-
amphetamine) hyperactivity, which proceeds to stereo-
typy at higher doses. The hyperactivity is considered to
be due predominantly to activation of limbic (i.e., nu-
cleus accumbens) DA D2 receptors, whereas the stereo-
typy is caused by stimulation of DA D2 receptors in the
dorsal striatal brain regions (Ellenbroek, 1993). Thus,
the greater potency of a drug to block agonist-induced
hyperactivity versus agonist-induced stereotypy is con-
sidered an indication of antipsychotic efficacy with re-
duced propensity to induce EPS. In this model, SGAs
more potently block hyperactivity than stereotypy, con-
sistent with the low level of EPS observed with SGAs
(for review, see Arnt and Skarsfeldt, 1998).
2. Conditioned Avoidance Responding. Dopamine D2
antagonists inhibit conditioned avoidance responding at
doses lower than those required to inhibit escape re-
sponding, and the doses of the various drugs are corre-
lated with their antipsychotic activity (Arnt, 1982).
However, most FGAs produce escape failures indicative
of motoric effects only slightly above the doses required
to block conditioned avoidance responses. In contrast,
SGAs effectively inhibit conditioned avoidance respond-
ing at doses that do not cause significant escape failures,
suggesting reduced propensity to produce EPS (Moore et
al., 1992, 1993; Seeger et al., 1995). Consistent with this
observation, SGAs compared with FGAs are more potent
in blocking agonist-induced hyperactivity or conditioned
avoidance responding than in causing catalepsy (Moore
et al., 1992; Arnt and Skarsfeldt, 1998). Furthermore,
long-term treatment of rats with SGAs did not produce
chronic jaw movements thought to model tardive dyski-
nesia, unlike treatment with FGAs (Gao et al., 1998;
Rosengarten and Quartermain, 2002).
3. Forelimb and Hind Limb Retraction Time (Paw
Test). The paw test is a paradigm established in rats
that distinguishes between EPS and the therapeutic
effects of APDs based on forelimb (FRT) and hind limb
retraction time (HRT) (Ellenbroek et al., 1987; Ellen-
broek, 1993). After receiving an injection of an APD, the
rats are placed on a platform that has four holes (two
holes for the forelimbs and two holes for the hind limbs).
The retraction times for the forelimbs and hind limbs
seem to be predictive of the EPS liability and therapeu-
tic efficacy (respectively) of APDs. FGAs such as halo-
peridol and chlorpromazine increase HRT and FRT at
equipotent doses, whereas SGAs such as clozapine and
olanzapine are more potent in increasing HRT than
FRT. Thus, it seems that the FRT is predictive of EPS
effects, whereas the HRT is predictive of treatment effi-
cacy. The paw test has been extensively characterized,
and more than 25 APDs have been shown to reliably
increase HRT. In a recent review, Geyer and Ellenbroek
(2003) concluded that the paw test has a high degree of
predictive validity and is effective in assessing antipsy-
chotic effects and EPS liability.
4. Drug Discrimination. Drug discrimination (DD)
has been used both to classify drugs in terms of their
subjective effects and to identify in vivo pharmacological
properties and mechanisms of drug action. DD with
clozapine as the training drug has proven to be useful as
a preclinical screen in the development of putative APDs
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(Millan et al., 1999b; Tang et al., 1997). The majority of
clozapine DD studies have been conducted with rats
trained to discriminate 5.0 mg/kg clozapine from vehicle
(Goudie and Taylor, 1998; Goudie and Smith, 1999;
Kelley and Porter, 1997; Wiley and Porter, 1992); how-
ever, recent studies suggest that a lower training dose of
clozapine may provide a more sensitive preclinical assay
for screening SGAs from FGAs (Goudie and Taylor,
1998; Goudie et al., 1998; Porter et al., 2000; Prus et al.,
2004, 2005). For example, Porter et al. (2000) trained
rats to discriminate 1.25 mg/kg clozapine from vehicle
and found that the SGAs olanzapine, risperidone, and
sertindole fully substituted for clozapine. These SGAs
had previously been shown not to substitute for cloza-
pine when the clozapine training dose was 5.0 mg/kg
(Goudie and Taylor, 1998). More SGAs seem to be “cloz-
apine-like” when a lower training dose is used, although
it should be noted that quetiapine produces only partial
substitution for clozapine at 1.25 mg/kg (Porter et al.,
2000), but substitutes fully for clozapine when a 5.0
mg/kg training dose is used (Goudie and Taylor, 1998).
Thus, the clozapine DD model can provide valuable in-
formation about the similarities and differences among
FGAs and SGAs that is useful for the development of
new drugs.
5. Electrophysiology and Brain Activation Patterns.
Electrophysiological studies have shown that long-term
treatment with FGAs reduces the number of spontane-
ously firing ventral tegmental area (A10) DA neurons
that project to limbic and cortical areas and of nigrostri-
atal (A9) DA neurons that project to the striatum
(Chiodo and Bunney, 1983; White and Wang, 1983). In
contrast, SGAs reduce the number of spontaneously fir-
ing DA neurons in the A10 area but not the A9 area,
consistent with their antipsychotic activity and reduced
EPS potential (Goldstein et al., 1993; Skarsfeldt, 1995;
Stockton and Rasmussen, 1996). Activation of the im-
mediate early gene c-fos and its protein product Fos has
been shown to be associated with increases in neuronal
activity including those induced by APDs (Robertson et
al., 1994; Deutch and Duman, 1996; Deutch et al., 1996;
Robertson and Fibiger, 1996). However, the pattern of
Fos expression differs, depending on the type of drug.
Fos expression is increased by FGAs and SGAs in the
nucleus accumbens, but expression is increased to
greater degree in the striatum by FGAs than SGAs.
Furthermore, SGAs uniquely increase Fos expression in
the prefrontal cortex.
In summary, numerous differences have been ob-
served between SGAs and FGAs in traditional animal
models of antipsychotic activity. These differences prob-
ably reflect the more variable receptor binding profile of
SGAs compared with FGAs and other potential as yet
unidentified mechanisms of action such as effects on
insulin signaling and glucose metabolism.
B. Neurotransmitter Regulation via Antipsychotic
Drugs
1. Dopamine and Antipsychotic Drugs. APDs act as
antagonists at the dopamine D2 receptor, reducing the
hypothesized overactivity in dopamine neurotransmis-
sion and, consequently, the positive symptoms of schizo-
phrenia. Whereas the FGAs are effective in alleviating
the positive symptoms of schizophrenia, they are less
effective or ineffective in reducing negative symptoms
and cognitive deficits, and they have been associated
with a number of side effects including extrapyramidal
symptoms (i.e., dystonia, akathisia, parkinsonism, and
tardive dyskinesia), hyperprolactemia, and weight and
metabolic effects (Lieberman et al., 2005a).
The SGAs are also effective in reducing the positive
symptoms of schizophrenia, and a meta-analysis of
FGAs and SGAs by Davis et al. (2003) suggested that
some SGAs (amisulpride, clozapine, olanzapine and ris-
peridone) may be clinically superior to FGAs. However,
not all studies or reviews support this position (Lieber-
man et al., 2005a; Jones et al., 2006; Lewis and Lieber-
man, 2008).
The proposal of clinical superiority of SGAs over the
FGAs are based on a number of observations (for review,
see Abi-Dargham and Laruelle, 2005) as follows:
• Improvements are seen in symptom domains other
than psychosis—negative symptoms, depression,
and anxiety.
• A lower incidence of extrapyramidal symptoms has
been observed in patients treated with SGAs than
with FGAs.
• Most SGAs share with clozapine a high 5-HT2A/D2
affinity ratio, which is thought to provide protection
against EPS and superiority in terms of negative
symptoms; 5-HT2A and D2 receptor antagonism
may act synergistically to increase prefrontal DA,
an effect not observed with selective D2 or 5-HT2A
receptor antagonists administered alone.
• SGAs show greater selectivity for the mesolimbic
DA system more than for the nigrostriatal DA sys-
tem: 1) SGAs show a dose-related selectivity for
affecting the firing of A10 versus A9 neurons and
for inducing gene expression in the nucleus accum-
bens versus the corpus striatum, 2) imaging studies
have shown that SGAs provide higher blockade of
D2 receptors in temporal cortex compared with the
striatum, whereas FGAs provide a similar level of
D2 receptor occupancy in both, and 3) several imag-
ing studies have reported higher extrastriatal occu-
pancies compared with striatal occupancies for
amisulpride, clozapine, olanzapine, quetiapine, ris-
peridone, and sertindole.
• Imagining studies show lower occupancies of stri-
atal D2 receptors at therapeutic doses of SGAs that
FGAs and suggest that clinical results obtained
after moderate occupancies (50–75%) are better
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than those obtained after high occupancies (75–
100%).
• SGAs are typically associated with a faster disso-
ciation from D2 receptors in rodents than FGAs, a
finding that may allow for a physiological synaptic
surge of DA to stimulate D2 receptors, supporting
the proposal of moderate D2 receptor blockade.
Although the initial treatment of patients with schizo-
phrenia may serve to decrease dopamine hyperactivity,
the long-term therapeutic use of APDs is known to elicit
dopamine supersensitivity (up-regulation of D2
High re-
ceptors) (for review, see Seeman et al., 2006). However,
not all antipsychotic drugs produce the same level of
dopamine supersensitivity or elevation of D2
High recep-
tors. In this regard, clozapine and quetiapine induce the
lowest elevation of D2
High receptors, in contrast to the
elevation elicited by haloperidol, risperidone, ziprasi-
done, and olanzapine. These differences probably reflect
the important differences in how tightly an antipsy-
chotic drug binds to the dopamine D2 receptor and the
rate of dissociation in vitro or in vivo (i.e., the fast-off-D2
principle) (Seeman and Tallerico, 1999).
Recently a meta-analysis of the single photon emis-
sion computed tomography and positron emission to-
mography in vivo receptor imaging literature was pub-
lished (Stone et al., 2008). Single photon emission
computed tomography and positron emission tomogra-
phy enable in vivo imaging of regional antipsychotic
medication binding to receptor subtypes in living pa-
tients with schizophrenia. SPECT The results of this
15-study meta-analysis revealed that both FGAs and
SGAs produce high temporal cortex D2/D3 receptor oc-
cupancy, whereas only FGAs produce high striatal
D2/D3 receptor occupancy. The extrapyramidal side ef-
fects were related primarily to striatal D2/D3 receptor
occupancy. The clinically effective dose correlated with
doses inducing maximal dopamine D2/D3 receptor occu-
pancy in both the striatum and temporal cortex, a strong
correlation occurring in the temporal cortex. It was con-
cluded that cortical dopamine D2/D3 receptor occupancy
is involved in antipsychotic efficacy, striatal D2/D3 occu-
pancy having a likely therapeutic role and also inducing
EPS.
2. GABA and Antipsychotic Drugs. A variety of dif-
ferent responses on GABAA receptor binding have been
observed in rodents treated with APDs or APDs com-
bined with benzodiazepines. Early studies showed that
haloperidol is associated with increases in the density of
GABA receptors (Frey et al., 1987; Gale, 1980; Huffman
and Ticku, 1983; See et al., 1989). In rats treated with
APDs for 28 days, [3H]muscimol binding was shown to
be decreased in the hippocampus and temporal regions
after 28 days of treatment with clozapine or olanzapine
but not after treatment with haloperidol or chlorprom-
azine (Farnbach-Pralong et al., 1998), a result that was
possibly suggestive of increased GABAergic neurotrans-
mission with SGAs. In contrast, Skilbeck et al. (2008)
reported that after 7 days of administration of haloper-
idol or olanzapine, [3H]muscimol binding density was
increased most prominently in the PFC after treatment
with either drug, although larger and more prolonged
effects were induced by olanzapine in subcortical re-
gions. After 28 days, no changes were observed in
[3H]muscimol binding in any region, although [3H]fluni-
trazepam binding density (Bmax) was increased for both
antipsychotic treatments in the PFC. They argued that a
subset of GABAA receptors sensitive to benzodiazepines
are regulated differently from other GABAA receptor
subtypes after antipsychotic drug administration in a
time- and region-dependent manner (Skilbeck et al.,
2008). It is possible that differences in dosing or brain
region examined may explain some of the differences
observed between these studies.
In rats treated with APDs for 6 months, Zink et al.
(2004b) reported increased expression of GAD67 in the
infralimbic cortex and anterior cingulate cortex and dif-
ferential effects of haloperidol and clozapine on
[3H]muscimol binding to GABAA receptors within corti-
cal, limbic, and subcortical areas. Haloperidol strongly
increased GABAA receptor binding in the striatum and
nucleus accumbens with reduced binding in the parietal
and temporal cortex. In contrast, clozapine had only
small effects in the basal ganglia and failed to elicit
major changes in these parts of the association cortex.
However, clozapine led to an increase in GABAA recep-
tor binding in limbic areas including the infralimbic
cortex and anterior cingulate cortex, whereas haloperi-
dol had a similar effect in the anterior cingulate cortex
but a smaller one in the infralimbic cortex. As discussed
by Zink et al. (2004b), the increased GABAA receptor
binding in the basal ganglia seen with haloperidol and
suggestive of reduced GABAergic tone may explain the
greater association of haloperidol treatment with extra-
pyramidal symptoms. In contrast, the increased GABAA
receptor binding in the limbic cortical regions seen to the
greatest extent with clozapine may reflect the positive
effects of clozapine on negative symptoms and cognitive
abilities.
Benzodiazepines can be also be used in conjunction
with atypical antipsychotics to treat schizophrenia, and
benzodiazepines can alter GABAA receptor density in
rat brain (Wu et al., 1994; Hutchinson et al., 1996, Toki
et al., 1996). McLeod et al. (2008) assessed the effects of
treatment with diazepam, haloperidol, or the combina-
tion of diazepam and haloperidol on GABAA binding
sites and found regionally selective increases in GABA
binding sites with diazepam or the combination of diaz-
epam and haloperidol. However, treatment with halo-
peridol alone decreased GABA binding sites in the thal-
amus and increased these sites in the hypothalamus. By
contrast, treatment with diazepam, haloperidol, and a
combination of the two drugs resulted in widespread
decreases in the number of benzodiazepine binding sites
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in the rat central nervous system, the notable exception
being increased numbers of benzodiazepine binding
sites in frontal cortex of rats that received diazepam
(McLeod et al., 2008).
Long-term treatment with clozapine or haloperidol
has also been shown to affect GABA transporter expres-
sion (Zink et al., 2004a). In adult male rats, clozapine or
haloperidol treatment resulted in up-regulation of GAT1
mRNA expression, whereas vesicular GABA transporter
expression declined in cortical and limbic brain regions,
and haloperidol showed a greater effect than clozapine.
GAT3 mRNA expression was suppressed in parietal and
temporal cortices.
3. Glutamate and Antipsychotic Drugs. APDs can
play a role in facilitating glutamatergic neurotransmis-
sion and lessening NMDA receptor hypofunction. In this
regard, there is evidence that long-term treatment with
haloperidol, clozapine, or raclopride can significantly re-
duce levels of the NMDA receptor endogenous antago-
nist kynurenic acid in the striatum, hippocampus, and
frontal cortex of rat brain (Ceresoli-Borroni et al., 2006).
APDs (e.g., haloperidol and clozapine) can increase
phosphorylation of the NR1 subunit of the NMDA recep-
tor (Leveque et al., 2000). In striatal culture, activation
of the cAMP pathway led to the phosphorylation of
897Ser-NR1 in a PKA-dependent manner. Thus, D2 an-
tagonists probably activate the NMDA receptor via
PKA-mediated phosphorylation of 897Ser-NR1. Haloper-
idol has been shown to increase NR1 phosphorylation
levels at S897 in vivo in the striatum as well as in a
neuronal culture system (Leveque et al., 2000). APDs
can also reduce oxidative stress in a number of neuro-
toxic models (see section III.H), resulting in a possible
reduction in the oxidative inhibition of the NMDA re-
ceptor. Of particular note, Steullet et al. (2006) demon-
strated that decreasing glutathione levels in slices of rat
hippocampus results in hypofunction of NMDA recep-
tors (for review, see Steullet et al., 2006). In PC12 cells,
SGAs olanzapine and quetiapine were able to restore
reductions in glutathione peroxidase activity observed
after exposure to -amyloid peptide (A25–35) (Wang et
al., 2005b). A number of studies have shown facilitatory
effects of clozapine on glutamate neurotransmission and
NMDA functioning primarily in cortex, whereas halo-
peridol seems to enhance glutamate levels and activity
at NMDA receptors primarily in the striatum (for re-
view, see Millan, 2005).
There is also evidence that haloperidol may inhibit
NMDA receptor function. Long-term treatment with
haloperidol but not with clozapine decreased NMDA
NR1 subunit expression within the primate dorsolateral
prefrontal cortex, a region involved in cognition and
negative symptoms (O’Connor et al., 2006). Similar find-
ings were observed in rat prefrontal cortex wherein pro-
longed treatment with haloperidol but not with olanza-
pine reduced the synaptic level of the obligatory NMDA
subunit NR1 and the regulatory NMDA subunit NR2A
and its scaffolding protein PSD95 and reduced traffick-
ing of GluR1 to the membrane (Fumagalli et al., 2008).
In addition, haloperidol altered the total and phosphor-
ylated levels of calcium calmodulin kinase type II at
synaptic sites and its interaction with regulatory NMDA
subunit NR2B (Fumagalli et al., 2008).
APDs as a whole do not seem to regulate D-serine or
its metabolic enzymes or glycine. Administration of hal-
operidol to rats did not significantly affect serine race-
mase or degrading enzyme DAAO (Verrall et al., 2007).
Previous work had shown a 2-fold elevation in DAAO
activity in patients with schizophrenia, the levels of
DAAO activity being the highest in patients with prior
antipsychotic drug use (Madeira et al., 2008). However,
long-term administration of haloperidol or clozapine for
21 days to mice did not alter DAAO activity, suggesting
that antipsychotic drug administration was not respon-
sible for the higher levels of DAAO activity seen in
patients with schizophrenia (Madeira et al., 2008). Of
interest, in chronically ill patients who were treated
with FGAs or SGAs, the glycine/serine ratio was signif-
icantly higher in patients treated with clozapine than in
those treated with FGAs or other SGAs and not different
from that in healthy subjects (Neeman et al., 2005).
Glycine agonists and transporter inhibitors have been
shown to potentiate the ability of FGAs and most SGAs
but not of clozapine to improve negative and cognitive
symptoms. This finding may reflect the fact that cloza-
pine itself can enhance activity at NMDA receptors (for
review, see Millan, 2005).
Several of the early studies assessing changes in glu-
tamate levels in the CSF, postmortem brain tissue, or
blood in patients with schizophrenia indicated increased
glutamate levels with antipsychotic drug therapy (Gat-
taz et al., 1985; Tsai et al., 1995; Tortorella et al., 2001;
van der Heijden et al., 2004), although not all (Korpi et
al., 1987; Alfredsson and Wiesel, 1989; Faustman et al.,
1999). Some studies have shown increases in glutamate
and/or aspartate levels in patients switched from FGAs
to SGAs (Evins et al., 1997; Goff et al., 2002), although in
at least one study a reduction was observed. In this
latter study, serum levels of aspartate, glutamate, and
other amino acids were elevated in patients with neuro-
leptic-resistant schizophrenia before clozapine treat-
ment, and 12 weeks after clozapine treatment a signifi-
cant reduction in serum levels of glutamate was
observed (Tortorella et al., 2001). However, in the study
of Tortorella et al. (2001), glutamate levels were already
elevated and increased further after exposure to SGAs.
In patients diagnosed with schizophrenia, bipolar disor-
der, or nonspecified psychosis at their first psychotic
episode, the observed decrease in plasma glutamate lev-
els was restored after treatment with APDs or APDs
combined with lithium or other mood stabilizers (Palo-
mino et al., 2007). Of interest, although the majority of
patients were treated with atypical antipsychotics, 7 to
11% were treated with typical antipsychotics and
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showed similar increases in plasma glutamate levels
(Palomino et al., 2007).
The mechanism of how APDs elevate glutamate levels
is not known, although a reduction in glutamate trans-
porter expression has been demonstrated in astrocytic
cultures treated with clozapine (Vallejo-Illarramendi et
al., 2005) and in rat brain after treatment with clozapine
or haloperidol (Schneider et al., 1998; Melone et al.,
2001; Schmitt et al., 2003). Interestingly, although both
clozapine and haloperidol decreased glutamate trans-
porter GLT-1 in the striatum, haloperidol resulted in
significantly greater reductions than those with cloza-
pine, a finding that may have relevance in neuroleptic-
induced movement disorders (Schneider et al., 1998).
APDs, and the SGAs in particular, can also up-regulate
the levels of neurotrophin BDNF (see section III.I), and
the time course of the medication-induced restoration of
plasma glutamate levels in patients who experienced
their first psychotic episode seemed to parallel that of
BDNF (Palomino et al., 2007).
a. N-Methyl-D-aspartate Antagonists in Animal Mod-
els. NMDA antagonists induce a number of changes in
animal models that resemble schizophrenia. In this sec-
tion, we review data from animal models assessing the
effects of SGAs and FGAs on regulation of NMDA an-
tagonists in behavioral and electrophysiological studies.
i. Behavioral activation. In rodents, NMDA antago-
nists induce behavioral activation that is characterized
by increased locomotor activity, ataxia, and stereotypic
head weaving. Both SGAs and FGAs can block the be-
havioral activation induced by NMDA antagonists, but
the SGAs are more selective. Corbett et al. (1995) found
that clozapine and olanzapine were substantially more
potent in blocking MK-801-induced behavioral activa-
tion than apomorphine-induced climbing. In contrast,
haloperidol was more potent in blocking effects of apo-
morphine than those of MK-801, and risperidone was
almost equipotent in blocking effects of both drugs. Clo-
zapine and olanzapine block the effects of PCP at doses
having no effect on baseline locomotor activity, whereas
haloperidol is effective only at doses that suppress nor-
mal activity (Gleason and Shannon, 1997). The differen-
tial effects of FGAs and SGAs on NMDA antagonist-
induced behavioral activation may be due to the 5-HT2
receptor-blocking properties of the SGAs, as similar ef-
fects are induced by selective 5-HT2 antagonists (Glea-
son and Shannon, 1997). The PCP-induced locomotor
hyperactivity was reversed after short-term administra-
tion of olanzapine or clozapine and after long-term 10-
month administration of olanzapine but not of haloper-
idol (Moy et al., 2004).
ii. Prepulse inhibition. Patients with schizophrenia
exhibit deficits in sensorimotor gating as indicated by
reduced prepulse inhibition (PPI) of startle responses
(Braff et al., 2001). In animal studies using PPI proce-
dures, deficits can be induced by DA agonists, 5-HT
agonists, and noncompetitive NMDA antagonists. Al-
though both FGAs and SGAs can block the disruptive
effects of dopaminergic agonists on PPI, most studies
showed that SGAs but not FGAs block the effects of
NMDA antagonists on PPI (Geyer et al., 2001). Cloza-
pine is more effective than haloperidol in blocking the
consequence of this experimentally induced NMDA re-
ceptor hypofunction (Keith et al., 1991; Bakshi et al.,
1994). Some of the newer SGAs (e.g., olanzapine, quetia-
pine, and ziprasidone) are also effective in blocking PPI
deficits induced by NMDA antagonists (Bakshi and
Geyer, 1995; Swerdlow et al., 1996; Mansbach et al.,
2001). Postnatal administration of PCP produced a def-
icit in PPI that was reversed by either pretreatment or
post-treatment with olanzapine (Wang et al., 2001). Fur-
thermore, similar to the rodent findings, clozapine
blocked PCP-induced disruption of PPI in monkeys,
whereas haloperidol did not (Linn et al., 2003).
iii. Social interactions. PCP can also disrupt normal
social interactions in rats. Pretreatment with clozapine
or olanzapine before injection of PCP reduced the dis-
ruption in social behavior induced by PCP (Corbett et
al., 1995). However, haloperidol and risperidone were
not effective in altering the effects of PCP in the social
interaction test (Corbett et al., 1995).
iv. Ketamine-induced activation of brain metabo-
lism. Subanesthetic doses of NMDA antagonists in-
duce robust increases in regional 2-deoxyglucose uptake
(Kurumaji et al., 1989; Duncan et al., 1998b) presum-
ably by disinhibiting neural circuits (Grunze et al., 1996;
Greene, 2001). The striking alterations in brain meta-
bolic activity patterns induced by subanesthetic doses of
ketamine are almost identical to those induced by the
selective NMDA antagonist MK-801 (Duncan et al.,
1999) indicating that the neuroanatomically selective
effects of ketamine result from reduced NMDA receptor
function. Pretreatment of rats with clozapine but not
with haloperidol blocked the brain metabolic activation
induced by ketamine (Duncan et al., 1998a). Clozapine
and olanzapine but not risperidone or haloperidol also
blocked ketamine-induced brain metabolic activation
(Duncan et al., 2000). Thus, the profile of the different
FGAs and SGAs in the ketamine-induced brain meta-
bolic activation model is similar to that reported for the
behavioral models described in section III.B.3.a.i.
v. Electrophysiological responses to N-methyl-D-aspar-
tate antagonists. Electrophysiological studies in vitro
indicate that SGAs can modulate responses to gluta-
mate and reverse the inhibitory effects of PCP on gluta-
mate-induced excitation. Haloperidol and clozapine
modulate the glutamate-mediated neurotransmission in
the rat medial prefrontal cortical slice with application
of both drugs markedly facilitating NMDA-evoked re-
sponses (Arvanov et al., 1997). Clozapine, but not halo-
peridol, produced bursts of excitatory postsynaptic po-
tentials (EPSPs) that were blocked by glutamate
receptor antagonists, suggesting that clozapine in-
creased release of excitatory amino acids in the prepa-
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ration (Arvanov et al., 1997). This latter finding is con-
sistent with in vivo work showing that short-term
clozapine but not haloperidol increases extracellular
concentrations of glutamate in the medial PFC of rats
(Daly and Moghaddam, 1993; Yamamoto et al., 1994).
Clozapine also increased the amplitude of EPSPs pro-
duced by stimulation of the corpus callosum, whereas
haloperidol decreased EPSP amplitude in this test sys-
tem (Arvanov et al., 1997). Clozapine preferentially po-
tentiated NMDA receptor-mediated transmission and
haloperidol depressed non-NMDA-mediated responses.
Robust electrophysiological enhancement of NMDA re-
sponses after corpus callosum stimulation was also
found for olanzapine, risperidone, and quetiapine but
not for chlorpromazine or loxapine (Ninan et al., 2003a).
These results suggest that the SGAs, in comparison with
the FGAs, could have very different effects on gluta-
mate-mediated transmission in vivo. However, there are
no studies available to demonstrate the effects of APDs
on NMDA receptor function in vivo.
Consistent with the findings of differential effects of
haloperidol and clozapine on NMDA receptor function,
clozapine, but not haloperidol, can prevent PCP-induced
blockade of NMDA responses in vitro (Wang and Liang,
1998). Furthermore, subchronic (7-day) treatment of
rats with PCP induces electrophysiological hypersensi-
tivity that is blocked by clozapine or olanzapine but not
haloperidol (Ninan et al., 2003b).
In vivo work has shown that administration of the
NMDA antagonist PCP can induce marked disruption of
the activity of pyramidal neurons in the rat PFC, in-
creasing the activity of 45% of pyramidal neurons re-
corded and decreasing the activity of 33%. PCP admin-
istration also markedly reduced cortical synchrony in
the delta frequency range (0.3–4Hz) as assessed by re-
cording local field potentials. The subsequent adminis-
tration of haloperidol or clozapine reversed PCP effects
on pyramidal cell firing and cortical synchronization
(Kargieman et al., 2007).
4. Other—Peptides and Antipsychotic Drugs. Admin-
istration of MK-801, a noncompetitive NMDA receptor
antagonist, increased levels of the neuropeptide-degrad-
ing enzymes, prolyl oligopeptidase and thimet oligopep-
tidase, in the posterior cingulate/retrospelenial cortices.
Clozapine but not haloperidol significantly attenuated
MK-801-induced changes in the levels of the neuropep-
tide-degrading enzymes in rat brain (Arif et al., 2007).
5. Intracellular Signaling Cascades and Antipsychotic
Drugs. The effects of FGAs and SGAs on neuronal sig-
naling systems are complex. FGAs and particularly
SGAs may interact with a number of cell surface recep-
tors including GPCR and some iontropic receptors either
directly or indirectly through neurotransmitter release
(Bymaster et al., 1996). Thus, the drugs may interact
with GPCRs and alter cAMP and IP3 second messen-
gers, depending on the receptors involved. In addition,
SGAs and FGAs may interact with GPCRs as antago-
nists, partial agonists, or inverse agonists, thereby add-
ing to their signaling complexity (Zorn et al., 1994:
Weiner et al., 2001; Bymaster et al., 1999; Olianas et al.,
1999; Shapiro et al., 2003). The process whereby the
interaction of FGAs and SGAs with cell surface recep-
tors or intracellular proteins results in long-term adap-
tive processes that produces their antipsychotic effects is
unknown. These long-term adaptive processes seem to
be important as antipsychotics take several weeks or
more for full effectiveness (Lieberman et al., 1993). Re-
cently, a number of studies have focused on the effects of
FGAs and SGAs on downstream signaling systems in-
cluding kinase cascades and transcriptional factors
(Pozzi et al., 2003; Browning et al., 2005; Lu and Dwyer,
2005).
In vitro and in vivo studies have shown that FGAs and
SGAs modulate mitogen-activated protein kinase sig-
naling cascades including Akt (protein kinase B) and
ERK (also called MAP kinase) signal transduction path-
ways. In vitro studies in hippocampal neuron cultures at
25 days demonstrated that 50 nM haloperidol and ris-
peridone significantly increased the levels of ERK phos-
phorylation (Yang et al., 2004). Clozapine, quetiapine,
and olanzapine significantly enhanced neurite out-
growth and Akt phosphorylation induced by NGF in
PC12 cells (Lu and Dwyer, 2005). In contrast, the FGAs
haloperidol, fluphenazine, and chlorpromazine reduced
neurite outgrowth and AKT phosphorylation induced by
NGF. In primary cultured rat cortical neurons, haloper-
idol induced apoptotic injury and reduced phosphoryla-
tion levels of Akt and activated caspase-3 (Ukai et al.,
2004).
In vivo studies showed that short-term administration
of haloperidol stimulated the phosphorylation of ERK1/2
in mouse dorsal striatum, whereas clozapine reduced
ERK1/2 phosphorylation (Pozzi et al., 2003). FGAs
caused mild activation of ERK in dorsal striatum and
superficial prefrontal cortex, whereas clozapine had no
effect in the striatum, but more widespread effects in
cortex (Valjent et al., 2004). In a short-term study 30
min after administration of clozapine, there was a selec-
tive increase in phosphorylation of prefrontal cortical
mitogen-activated protein kinase kinase 1/2 and ERK,
which was reversed by administration of a 5-HT2A re-
ceptor agonist (Browning et al., 2005). Short-term treat-
ment with haloperidol and olanzapine produced a gen-
eral reduction in ERK1/2 phosphorylation in rat
prefrontal cortex in the nuclear and cytosolic compart-
ments, an effect Browning et al. (2005) suggested may be
the result of blockade of dopaminergic and serotonergic
receptors. However, olanzapine treatment for 14 days
resulted in an increase in ERK1/2 phosphorylation in
the nuclear and membrane compartments at various
time points after sacrifice. Long-term haloperidol ad-
ministration did not alter ERK1/2 phosphorylation.
Thus, FGAs and SGAs can modulate ERK phosphoryla-
tion and activity and thus modulate neuronal vitality,
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survival, and plasticity and some, but not all, studies
suggest that there are differential effects between the
two groups of drugs.
Long-term administration of haloperidol to rats sig-
nificantly reduced phosphorylated GSK-3 protein lev-
els in frontal cortex, whereas long-term administration
of clozapine caused significant elevation of protein levels
(Kozlovsky et al., 2006). In another study, significant
increases in the levels of total protein were identified
after administration of clozapine, haloperidol, or risperi-
done (Alimohamad et al., 2005). Short-term treatment of
mice with SGAs including risperidone, clozapine, olan-
zapine, quetiapine, and ziprasidone rapidly increased
the level of brain phosphorylated GSK-3 in the cortex,
hippocampus, striatum, and cerebellum in a dose-depen-
dent manner (Li et al., 2007). Haloperidol and clozapine
increased phosphorylation of GSK-3/ in rat frontal
cortex, whereas clozapine increased phosphorylation of
Akt for 1 h, and the response to haloperidol was tran-
sient (Roh et al., 2007). Overall, SGAs increase phos-
phorylation of GSK-3, resulting in inhibition of its ac-
tivity, consistent with increased activity of Akt. The
effects of FGAs on GSK3 are controversial.
Antipsychotic treatment has been suggested to re-
quire cAMP-induced PKA activation and subsequent
phosphorylation of nuclear proteins. PKA-deficient mice
do not demonstrate haloperidol-induced catalepsy and
fail to induce Fos in striatal regions (Adams et al., 1997).
CREB is a downstream target of PKA, and short-term
haloperidol treatment in rats enhanced phosphorylation
of the transcription factor CREB in striatum (Konradi et
al., 1993). Short-term administration of haloperidol or
olanzapine to mice increased PKA activity in dorsal stri-
atum and had no effect in nucleus accumbens, whereas
olanzapine decreased PKA activity in medial prefrontal
cortex (Turalba et al., 2004). Olanzapine reduced phos-
phorylated CREB immunoreactivity in medial prefron-
tal cortex, consistent with reduced activity of PKA, but
haloperidol and olanzapine were without effect in nu-
cleus accumbens and striatum. A short-term study
showed that haloperidol stimulated the phosphorylation
of CREB in mouse dorsal striatum, but, in contrast,
clozapine reduced CREB phosphorylation (Pozzi et al.,
2003). Long-term, but not short-term, clozapine in-
creased PKA activity in rat cortex, hippocampus, and
striatum, whereas long-term, but not short-term, halo-
peridol increased activity of PKA only in striatal areas
(Dwivedi et al., 2002.). However, a PKA inhibitor did not
block the dopamine D2 antagonist eticlopride-induced
Fos expression (Adams and Keefe, 2001), raising ques-
tions about the role of phosphorylation of CREB in the
effects of haloperidol. Long-term treatment of mice with
haloperidol produced increases in the guanosine 5-O-(3-
thio)triphosphate-mediated adenylyl cyclase activity in
mouse frontal cortex, whereas olanzapine caused re-
duced activity. In striatum, olanzapine treatment signif-
icantly reduced the activity, whereas the effect of halo-
peridol treatment was not significantly different from
the control (Kaplan et al., 1999).
6. Effects of Antipsychotic Drugs on Monoamine and
Amino Acid Neurotransmitter Efflux. The differential
release of monoamines and amino acids by the SGAs and
FGAs has been suggested to account for some of the
clinically relevant differences observed between these
two classes of drugs, as well as differences among drugs
within the class of SGAs. Because of the likely effects of
neurotransmitters on neuronal activation and metabo-
lism, altered efflux of monoamines and amino acids may
be involved in the neuroprotective properties of SGAs.
a. Dopamine and Norepinephrine Extracellular Con-
centrations. Decreased dopaminergic activity in the
cortex of patients with schizophrenia has been inferred
on the basis of cerebrospinal fluid and imaging studies
(Weinberger et al., 1988), but no direct evidence for this
inference has been offered. However, altered DA D1 re-
ceptor density has been related to impaired working
memory in patients with schizophrenia (Okubo et al.,
1997; Abi-Dargham et al., 2002). Thus, it has been sug-
gested that cognitive deficits in schizophrenia may be
related, in part, to diminished cortical dopaminergic or
noradrenergic activity or both (Meltzer and McGurk,
1999).
In microdialysis studies, Invernizzi et al. (1990) first
reported the ability of clozapine, the prototypical SGA,
to increase the efflux of cortical DA in the rat. Subse-
quently, many studies have shown that clozapine pref-
erentially increases DA efflux in the cortex compared
with that observed in the dorsal and ventral striatum
(Moghaddam and Bunney, 1990; Kuroki et al., 1999).
Other SGAs including olanzapine, quetiapine, risperi-
done, ziprasidone, and zotepine have been shown to
have a preferential ability to increase cortical DA efflux
(Volonte´ et al., 1997; Li et al., 1998; Kuroki et al., 1999;
Rowley et al., 2000; Zhang et al., 2000), and for cloza-
pine, risperidone, olanzapine, the increase in DA release
occurs after long- and short-term administration. SGAs,
but not FGAs, also increase cortical norepinephrine ef-
flux in prefrontal cortex (Li et al., 1998; Rowley et al.,
1998; Zhang et al., 2000). The SGAs have also been
shown to increase the efflux of both neurotransmitters
in the hippocampus (Chung et al., 2004). Aripiprazole, a
partial DA D2/D3 agonist, which is also a serotonergic
5-HT2A inverse agonist and 5-HT1A partial agonist, has
been shown to increase DA release in the medial pre-
frontal cortex and hippocampus after short- and long-
term administration (Li et al., 2004). However, one
study showed that aripiprazole produced no change in
prefrontal cortical DA efflux (Jordan et al., 2004). Re-
cently, an increase in DA efflux in cortical regions by
aripiprazole has been reported in the mouse (Zocchi et
al., 2005).
The ability of the SGAs to increase cortical DA release
is correlated with their affinity for 5-HT2A receptors
(Kuroki et al., 1999). However, 5-HT2A inverse agonists
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such as M100907 increase cortical DA efflux only when
combined with low doses of D2 blockers such as haloper-
idol (Lie´geois et al., 2002). Moreover, M100907 is inef-
fective in increasing DA efflux in the cortex in the pres-
ence of high-dose (1.0 mg/kg) haloperidol. Other 5-HT2A
inverse agonists such as SR46349B increase DA efflux in
the cortex when combined with haloperidol (Rinaldi-
Carmona et al., 1992; Bonaccorso et al., 2002), and 2A
receptor blockade can also potentiate the ability of the
D2 antagonist, raclopride, to increase cortical DA release
(Hertel et al., 1999).
b. Serotonin Extracellular Concentrations. The
SGAs, with the exception of aripiprazole, all share
5-HT2A receptor antagonism but have a varied effect on
other 5-HT receptors. Some are 5-HT2C, 5-HT6, and
5-HT7 antagonists, as well as 5-HT1A partial agonists.
All have been shown to enhance DA efflux by a 5-HT1A-
dependent mechanism (Ichikawa et al., 2001). 5-HT1A
agonism may inhibit the firing of 5-HT neurons in the
raphe and, thus, decrease 5-HT release in terminal re-
gions. Risperidone (1 or 2 mg/kg) and clozapine (20 mg/
kg) significantly increased extracellular 5-HT levels in
the medial prefrontal cortex and the nucleus accumbens
of rats, respectively (Hertel et al., 1996; Ichikawa et al.,
1998). Olanzapine (1 and 10 mg/kg), S()-sulpiride (10
and 25 mg/kg), haloperidol (0.1 and 1 mg/kg), and the
selective 5-HT2A receptor antagonist M100907 (1 mg/kg)
had no significant effect on extracellular 5-HT levels in
either region (Ichikawa et al., 1998). Thus, the ability to
increase extracellular 5-HT levels in the medial prefron-
tal cortex and the nucleus accumbens by these APDs is
not directly related to their affinity for 5-HT2A receptors,
as olanzapine and M100907 had no significant effect on
extracellular 5-HT levels.
c. Acetylcholine Extracellular Concentrations. SGAs,
with the exception of aripiprazole, have been shown to
increase the efflux of ACh in the rat medial prefrontal
cortex and hippocampus (Parada et al., 1997; Ichikawa
et al., 2002; Shirazi-Southall et al., 2002; Chung et al.,
2004). This effect is blocked by the cholinergic M1 recep-
tor antagonist telenzepine (Li et al., 2005), suggesting
that the ACh efflux is due to activation of cholinergic
cortical inputs. Given the observed effects of muscarinic
agonists on cognitive behaviors in a variety of animal
models, it is highly likely that the increased efflux of
ACh is relevant to the ability of the SGAs to improve
cognition.
d. Glutamate and GABA Extracellular Concentrations.
There have been numerous in vivo microdialysis studies
on the effect of haloperidol and clozapine, as well as
other APDs, in modulating the efflux of glutamate or
aspartate in the cortex or striatum. The results are
mixed, reflecting differences in dosages, duration of
treatment, use of anesthesia, and the difficulty of sepa-
rating glutamate efflux that is neuronally based from
that of the amino acid compartment (Yamamoto et al.,
1994). Pietraszek et al. (2002) reported that 6 weeks of
treatment with clozapine, followed by its withdrawal for
4 days, lowered both the basal and the stimulated levels
of glutamate and aspartate. In contrast, a 6-week treat-
ment with haloperidol, followed by withdrawal, elevated
the basal but not the veratridine-stimulated extracellu-
lar levels of glutamate and aspartate. Haloperidol, but
not clozapine, enhanced the activity of cortical neurons.
In a study of the effect of these two APDs on glutamate
release from nerve terminals isolated from rat prefron-
tal cortex, Yang and Wang (2005) found that both halo-
peridol and clozapine inhibited glutamate release by ion
channel activities that influence nerve terminal excit-
ability. At the present time, the effects of APDs on glu-
tamate release cannot be related to their therapeutic
actions with any degree of confidence. Short-term sys-
temic administration of clozapine markedly and admin-
istration of haloperidol to a much lesser extent reduced
extracellular GABA levels in prefrontal cortex in awake
rats without altering striatal GABA efflux (Bourdelais
and Deutch, 1994). Thus, release of GABA from inter-
neurons in the prefrontal cortex is inhibited by both
FGAs and SGAs.
In summary, although variations do exist across stud-
ies and in the plethora of findings reported, compared
with most SGAs, FGAs, as represented by haloperidol,
show specific pharmacological differences including 1)
the highest occupancy of striatal D2 receptors with a
slow dissociation rate from the receptor indicating
greater overall blockade, 2) regionally selective in-
creased efflux in neurotransmitter release of DA and
acetylcholine particularly after long-term administra-
tion, 3) evidence for decreasing expression of the NR1
subunit of the NMDA receptor, which would reduce
NMDA receptor function, and 4) greater selectively for
increased glutamatergic neurotransmission within the
basal ganglia. In addition, FGAs and SGAs in several
instances had distinctly different effects on intracellular
signaling cascades in brain. Of particular note, SGAs
had more effects on cortical signaling cascades than
FGAs, consistent with their effects in many systems in
cortical areas.
C. Neuroanatomical Plasticity after Treatment with
Antipsychotic Drugs
In a longitudinal, controlled, double-blind clinical
trial, Lieberman et al. (2005b) reported significant re-
ductions in gray matter volume in first-episode patients
who were treated with haloperidol, but only a slight and
nonstatistically significant reduction in patients who
were treated with olanzapine. This finding suggested
that olanzapine seemed to ameliorate neurodegenera-
tive changes in the brain occurring either as a progres-
sion of the disease and/or exposure to the FGA haloper-
idol. Reductions in gray matter have been reported
previously in first-episode schizophrenia patients who
received primarily FGAs (DeLisi et al., 1997; Gur et al.,
1998; Lieberman et al., 2001a; Cahn et al., 2002). In
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addition, van Haren et al. (2007) found that treatment
with clozapine and olanzapine was associated with less
reduction in gray matter signal intensity than treatment
with haloperidol in patients with schizophrenia followed
longitudinally for up to 5 years and undergoing serial
magnetic resonance imaging scans.
It is noteworthy that caudate enlargement has been
encountered primarily with FGAs and not with SGAs
(Chakos et al., 1994; Corson et al., 1999; Andersson et
al., 2002). The functional significance of caudate hyper-
trophy is presently unclear, but it may be related to the
induction of EPS by the FGAs (Keshavan et al., 1994). In
rats, striatal enlargement was most evident in the ani-
mals that developed high vacuous chewing movements,
a potential animal model of TD (Chakos et al., 1998). In
patients with schizophrenia, larger caudate volumes
have been associated with poor performance on neuro-
psychological tests (Hokama et al., 1995), the deficit
syndrome (Buchanan et al., 1993), and greater severity
of symptoms (Gur et al., 1998).
Clozapine has been reported to reverse the increases
in basal ganglia volume that are associated with FGA
drug therapy (Chakos et al., 1995; Scheepers et al.,
2001a). In treatment-resistant patients who responded
to clozapine treatment, the degree of reduction in the left
caudate volume was significantly related to the extent of
improvement in positive and general symptoms (Scheep-
ers et al., 2001b). In a study of first-episode patients,
caudate volume increases were observed after treatment
with haloperidol but not after treatment with olanzap-
ine (Lieberman et al., 2005b). This finding confirms re-
sults of an earlier study suggesting that SGAs do not
produce an increase in basal ganglia volume (Corson et
al., 1999). However, a recent study of patients with
neuroleptic-naive, first-episode schizophrenia reported
an increase in basal ganglia volume in patients treated
with risperidone (Massana et al., 2005). In addition,
Molina et al. (2005) found increases in gray matter vol-
ume in neuroleptic-naive patients treated with risperi-
done and neuroleptic-resistant patients treated with clo-
zapine (Molina et al., 2005).
In an attempt to define the mechanism underlying the
ability of SGAs such as olanzapine and clozapine to
prevent volume loss in the PFC in schizophrenia, Wang
and Deutch (2008) subjected rats to lesions disrupting
the DA innervation of the PFC and then 3 weeks later, a
time point when a large decrease in dendritic spine
density and length was observed, assigned animals ran-
domly to receive haloperidol, olanzapine, or vehicle ad-
ministration for 3 weeks (Wang and Deutch, 2008). The
animals were then sacrificed, and layer V pyramidal
cells in the prelimbic (area 32) PFC were reconstructed
from Golgi-impregnated material. Strikingly, olanzap-
ine reversed the dystrophic changes in dendrites of layer
V pyramidal cells, whereas haloperidol did not provide
any benefit. Neither olanzapine nor haloperidol treat-
ment of sham-lesioned animals changed the dendritic
trees of pyramidal cells, suggesting that there is not a
direct neurotoxic effect of haloperidol.
The ability of the SGA olanzapine to reverse dystro-
phic changes in pyramidal neuron dendrites suggests
that dystrophic changes in dendrites of pyramidal cells
may be a factor responsible for the decrease in cortical
volume in patients with schizophrenia. One possible rea-
son for this is that some SGAs increase DA tone in the
PFC, which may slow progressive morphological
changes in schizophrenia. Consistent with this specula-
tion, SGAs (e.g., clozapine and olanzapine) but not hal-
operidol increase extracellular DA concentrations in the
PFC (Li et al., 1998). The loss of dendritic spines also
suggests that the presynaptic elements that normally
form synapses with spines either retract or reroute to
synapse onto a different site, possibly causing the
changes in cortical connectivity seen in schizophrenia. A
retraction of presynaptic elements that pairs with spines
may account for the decreased expression of a group of
genes associated with presynaptic elements in schizo-
phrenia, as uncovered in gene array studies (Mirnics et
al., 2001a).
The data of Wang and Deutch (2008) on dendritic
spine recovery in response to treatment with an SGA are
also striking because the response to the SGA was com-
plete recovery of dendritic elements rather than some
attenuation of the loss of spines or dendritic length. It is
not yet known whether starting an SGA at a time point
later than 3 weeks after cortical DA denervation will
attenuate but not completely reverse the changes in
pyramidal cell dendrites. However, the complete rever-
sal in animal studies offers the exciting possibility that
intervention with a suitable APD at an appropriate time
point may not only prevent further volume changes in
schizophrenia but also actually reverse dystrophic neu-
ronal changes, including those in patients with a long
duration of illness.
In summary, recent evidence suggests that SGAs can,
to varying degrees, mitigate and in some cases reverse
some of the morphological changes observed in patients
with schizophrenia, including gray matter volume re-
ductions, caudate hypertrophy, white matter volume in-
creases, and decreases in dendritic spine density and
length observed within the prefrontal cortex. The mech-
anisms underlying these changes need to be defined but
may reflect important differences between SGAs and
FGAs in receptor binding profiles, oxidative stress pa-
rameters, regulation of neuromodulators, and neurotro-
phic factors.
D. Apoptosis and N-Methyl-D-aspartate Antagonist-
Induced Neurodegeneration
In this section, we review data from animal models
assessing the effects of APDs on the effects of NMDA
antagonist-induced glutamate release and neurodegen-
eration and in other animal models of apoptosis.
382 LIEBERMAN ET AL.
NMDA antagonists stimulate the release of several
neurotransmitters within the brain. In the rat prefron-
tal cortex, short-term administration of NMDA antago-
nists stimulates the release of glutamate (Moghaddam
et al., 1997; Adams and Moghaddam, 2001; Lorrain et
al., 2003), dopamine (Schmidt and Fadayel, 1996;
Moghaddam and Adams, 1998; Mathe´ et al., 1999), and
serotonin (Martin et al., 1998; Millan et al., 1999a; Ad-
ams and Moghaddam, 2001; Amargo´s-Bosch et al.,
2006). Clozapine and haloperidol both blocked the MK-
801-induced increase in glutamate in rat medial pre-
frontal cortex, whereas only clozapine was able to block
the increased efflux of serotonin (Lo´pez-Gil et al., 2007).
Only systemic administration of MK-801 and not local
administration within the prefrontal cortex resulted in
an increased efflux of glutamate and serotonin, suggest-
ing that NMDA receptor blockade was occurring distal
to the prefrontal cortex. In contrast, both systemic and
local administration of clozapine or haloperidol could
block the effects of MK-801, indicating that the medial
prefrontal cortex was a site of action of these two APDs.
Abekawa et al. (2006) also reported that clozapine and
haloperidol dose relatedly attenuated PCP-induced hy-
perlocomotion, and concentration dependently blocked
PCP-induced short-term increases in glutamate levels in
the medial PFC but with locomotor activity in the saline-
treated group reduced to a lesser extent by clozapine
than haloperidol. In contrast, Adams and Moghaddam
(2001) reported no effect of haloperidol, clozapine, or the
5-HT2A antagonist, M100907, on the hyperglutamater-
gic effects of PCP. Overall, these findings suggest that
both FGAs and SGAs can reverse some of the effects of
NMDA receptor antagonists (i.e., short-term increase in
glutamate release).
Early work demonstrated efficacy for both FGAs and
SGAs in preventing NMDA antagonist neurotoxicity
(Farber et al., 1993). However, a subsequent study
showed differences among APDs on the basis of their
potency in blocking MK-801 neurotoxicity, demonstrat-
ing that olanzapine, clozapine, and fluperlapine segre-
gated into a high-potency group for blocking neurotoxic
effects, followed by the three typical antipsychotics (hal-
operidol, loxapine, and thioridazine) as a moderate po-
tency group, the antidepressant amoxapine being the
least effective of all (Farber et al., 1996). Fujimura et al.
(2000) reported similar findings showing that pretreat-
ment (15 min) with clozapine or olanzapine but not with
risperidone or haloperidol blocked the neuronal vacuol-
ization produced by dizocilpine and significantly atten-
uated the expression of Fos-like protein in the retrosple-
nial cortex of rats. These findings suggest that some
antipsychotics and in particular olanzapine and cloza-
pine may be more effective than other APDs in reducing
neurodegenerative changes associated with the admin-
istration of an NMDA antagonist.
Similar results have been more recently obtained in
neonatal rats administered olanzapine in conjunction
with repeated doses of PCP (Wang et al., 2001). In this
study, the characteristics of neuronal loss, as well as
Western blot analysis of Bac and Bcl-2 expression, sug-
gest that PCP induced progressive apoptotic neuronal
death in the cortex and olanzapine ameliorated these
effects. In addition, in neonatal rats exposed to intra-
ventricular kainic acid (Humphrey et al., 2002), admin-
istration of olanzapine and the antioxidant, melatonin,
but not haloperidol ameliorated apoptotic neuronal loss
in the hippocampus (Csernansky et al., 2006).
Long-term administration of methamphetamine trig-
gers a mitochondria-dependent induction of apoptotic
cascades and altered Bcl-2 expression that results in
selected brain lesions. Long-term olanzapine exposure
reduces methamphetamine-induced mortality and ty-
rosine hydroxylase immunoreactivity and prevents
Bcl-2 decreases (He et al., 2004). Likewise, quetiapine
counteracts anxiety-like behavioral changes that occur
after long-term methamphetamine exposure (He et al.,
2005a).
Okadaic acid is a protein phosphatase-2A inhibitor
used to increase tau phosphorylation and induce neuro-
nal death in models of Alzheimer’s disease and has been
shown to result in neurodegeneration and a spatial
memory deficit after injections into the hippocampus of
rats (He et al., 2001). Olanzapine pretreatment was able
to block both the okadaic acid-induced hippocampal cell
death and impairment in spatial memory (He et al.,
2005b). Repeated stress also leads to a reduction in the
hippocampal expression of Bcl-2 in addition to a reduc-
tion in BDNF levels, and these effects can be blocked by
long-term olanzapine treatment (Luo et al., 2004).
Not all SGAs have the ability to block apoptotic neu-
rodegeneration. For example, the catechol and hydroqui-
none metabolites of remoxipride, a substituted benz-
amide-type APD, has been shown to induce apoptosis in
HL60 cells and human bone marrow progenitor cells
(McGuinness et al., 1999).
Recently, olanzapine and quetiapine were observed to
block the activation of caspase-3, an enzyme involved in
apoptosis (Wang et al., 2005b). In addition, these drugs
blocked overproduction of intracellular free radicals in
PC12 cells exposed to A, which is the major constituent
of amyloid plaques found in Alzheimer’s disease and
known to be toxic in a variety of cell cultures (Wang et
al., 2005b). In addition, clozapine or olanzapine admin-
istration for 28 days has been shown to up-regulate
Bcl-2 gene expression in the frontal cortex and hip-
pocampus (Bai et al., 2004).
In summary, although both FGAs and SGAs can mit-
igate increases in glutamate release associated with
short-term administration of NMDA antagonists, SGAs
seem to enhance cell survival to a greater extent than
FGAs. Beyond the familiar effects of SGAs on monoam-
inergic and cholinergic neurotransmitter receptors and
possible links against excitotoxic damage (Farber et al.,
1998; Olney et al., 1999), SGAs in varying degrees may
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have properties that promote cell survival via antiapop-
totic effects on the molecular cascade associated with
apoptosis as shown here. In addition, some SGAs may
facilitate cell survival via an ability to increase neuro-
active steroids, reduce oxidative stress, and to facilitate
neurotrophic factor expression as discussed in the next
section.
E. Second-Generation Antipsychotic Drugs Increase
Neuroactive Steroids in Animal Models
In animal models, olanzapine (Marx et al., 2000, 2003)
and clozapine (Barbaccia et al., 2001; Marx et al., 2003)
but not haloperidol dose dependently increase ALLO
levels in rodent cerebral cortex. Olanzapine also in-
creases ALLO levels in rodent hippocampus (Marx et al.,
2006a). It has been hypothesized that olanzapine- and
clozapine-induced elevations in ALLO may represent a
potential mechanism contributing to the therapeutic ef-
ficacy of these agents (Marx et al., 2003, 2005). Recent
reports that ALLO administration potentiates the ac-
tions of olanzapine on DA-mediated rodent behaviors
further support the possibility that ALLO induction may
be relevant to antipsychotic therapeutic mechanisms
(Ugale et al., 2004).
In addition to a potential impact on GABAergic neu-
rotransmission, clozapine- and olanzapine-induced ele-
vations in ALLO may also result in neuroprotective and
neurotrophic effects. For example, ALLO is neuroprotec-
tive against kainic acid- and NMDA-induced excitotox-
icity (Lockhart et al., 2002; Ciriza et al., 2004) and
contusion injury (Djebaili et al., 2004) and demonstrates
anticonvulsant actions in a number of rodent seizure
models (Belelli et al., 1989; Kokate et al., 1994, 1996;
Devaud et al., 1995). ALLO administration doubles the
lifespan of Niemann-Pick type C mice and delays the
onset of neurological symptoms in this model (Griffin et
al., 2004). ALLO also increases proliferation in human
and rodent neuronal stem cells (Wang et al., 2005c).
Antipsychotic-induced changes in ALLO may thus play
a role in the regulation of a number of functionally
relevant central nervous system events.
Neuroactive steroids also affect myelination. For ex-
ample, ALLO administration in vitro increases myelin
basic protein expression (Ghoumari et al., 2003), and the
ALLO precursor progesterone, a steroid that can be syn-
thesized in the brain and in the periphery, also affects
myelination (Schumacher et al., 2000; Ibanez et al.,
2003). Both clozapine and olanzapine dose dependently
increase progesterone in rodents (Barbaccia et al., 2001;
Marx et al., 2003, 2006a). If alterations in ALLO and
progesterone also occur in patients with schizophrenia
after antipsychotic drug administration, these changes
could be relevant to myelin regulation, a process that
seems to be dysregulated in subjects with schizophrenia
(Hakak et al., 2001; Tkachev et al., 2003). Progesterone
is also neuroprotective against cerebral contusion injury
(Roof et al., 1994; Djebaili et al., 2004) and ischemia
(Jiang et al., 1996; Gibson et al., 2005; Moralí et al.,
2005).
Finally, recent data suggest that clozapine and olan-
zapine also elevate the neuroactive steroid pregnenolone
in rodent hippocampus (Marx et al., 2006a), a potential
precursor to many other neuroactive steroids. Preg-
nenolone (Flood et al., 1992) and pregnenolone sulfate
(Flood et al., 1992, 1995; Valle´e et al., 1997, 2003; Akwa
et al., 2001) demonstrate pronounced effects on learning
and memory in rodents and deficits in this neuroactive
steroid have been linked to depression in humans
(George et al., 1994). Clozapine- and olanzapine-induced
elevations in pregnenolone could be relevant to cognitive
deficits and depressive symptoms in patients with
schizophrenia.
In subjects with schizophrenia or bipolar disorder,
median ALLO levels were 67% higher in the posterior
cingulate in subjects who were receiving clozapine at the
time of death compared with subjects with these disor-
ders who were not receiving clozapine at this time point,
although these results did not achieve statistical signif-
icance (Marx et al., 2006b). Given the small sample sizes
in human postmortem tissue studies, however, type II
error cannot be excluded. Earlier work demonstrated a
role for ALLO in antidepressant-like (Khisti and
Chopde, 2000; Khisti et al., 2000; Pinna et al., 2003) and
anxiolytic-like (Crawley et al., 1986; Wieland et al.,
1991; Brot et al., 1997) effects in rodent models, and low
ALLO levels have been linked to depressive symptoms
in humans (Uzunova et al., 1998).
In summary, the SGAs olanzapine and clozapine can
increase ALLO levels in rodent brain, and ALLO has
been shown to be neuroprotective in models of excitotox-
icity, to increase proliferation of human and rodent neu-
ronal stem cells, and to potentially regulate myelination.
In fact, both olanzapine and clozapine can elevate other
neurosteroids including progesterone and pregnenolone.
Only one study to date has reported a trend for increases
in ALLO levels in patients with schizophrenia who were
receiving clozapine at the time of their death. Additional
studies are necessary in patients with schizophrenia to
understand how neurosteroids and their metabolic path-
ways may be dysregulated in schizophrenia and the role
that SGAs can play in restoring neurosteroid levels.
F. Effects of Antipsychotic Drugs on Mitochondria and
Oxidative Phosphorylation
APDs have a negative impact on energy metabolism
via inhibition of the electron transport system, although
some drugs show significantly greater inhibition than
others. Alterations in energy metabolism have been sug-
gested to reflect a greater risk for development of tardive
dyskinesia.
1. Impaired Mitochondrial Function and Risk for Tar-
dive Dyskinesia. Because schizophrenia has histori-
cally been associated with alterations in the dopamine
system, the development of APDs has been guided by the
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ability of potential new drugs to bind DA receptors.
Thus, both FGAs and SGAs ameliorate schizophrenic
symptoms most certainly by acting as DA receptor block-
ers. Over time, however, enthusiasm for the FGAs as a
treatment for schizophrenia has been tempered by the
fact that extended use of FGAs is correlated with the
onset of TD. Some evidence suggests that impairment of
mitochondrial function may be related to FGA-induced
extrapyramidal symptoms such as TD, for example, 1)
alterations in brain energy metabolism have been dem-
onstrated in human patients symptomatic for TD (Goff
et al., 1995) and 2) vacuous chewing movements, the
rodent equivalent of TD, can be induced by long-term
treatment with haloperidol (Andreassen and Jørgensen,
2000; Rosengarten and Quartermain, 2002) or the mito-
chondrial toxin, 3-nitropropionic acid (Andreassen and
Jørgensen, 1995).
2. Antipsychotic Drugs Differentially Inhibit Complex
I Activity. In vitro, several FGAs have been shown to
interfere with the enzymes of the electron transport
pathway in isolated mitochondrial membranes and
brain homogenates (Burkhardt et al., 1993; Maurer and
Mo¨ller, 1997; Modica-Napolitano et al., 2003). The site of
the greatest inhibitory effect of FGAs is respiratory com-
plex I, the NADH-oxidizing enzyme first in the electron
transport sequence. Strong inhibition of complex I activ-
ity is observed in isolated mitochondria after the admin-
istration of the FGAs, chlorpromazine, thioridazine, and
haloperidol. In contrast, risperidone and quetiapine
have only mild inhibitory effects, and olanzapine and
clozapine have barely measurable effects on complex I
activity (Modica-Napolitano et al., 2003). Long-term ad-
ministration of haloperidol or fluphenazine results in a
generalized reduction in complex I activity in rat brain
tissue, whereas long-term administration of clozapine
has no effect on complex I activity (Prince et al., 1997).
Altogether, in vivo and in vitro studies consistently dem-
onstrate greater potency of FGAs versus SGAs as inhib-
itors of complex I activity.
Although separate assays have traditionally been
used for each step in the electron transport pathway, an
integrated assay has been developed to assess the rela-
tive ability of FGAs and SGAs to inhibit the entire
electron transport pathway in intact mitochondria. This
is an in vitro assay that includes the sequential activi-
ties of respiratory complexes I, III, and IV, comprising
the complete sequence for stepwise oxidative transfer of
electrons from NADH to oxygen. This integrated assay
may be a better indication of any possible rate-limiting
effect of site-specific drug inhibition on respiration over-
all (Modica-Napolitano et al., 2003). The drug potency
for respiratory inhibition measured in the integrated
assay was chlorpromazine  risperidone  haloperi-
dol  quetiapine. Clozapine and olanzapine did not in-
hibit at all, and the insolubility of thioridazine limited
its testing in this assay (see Fig. 3 in Modica-Napolitano
et al., 2003). Except for risperidone and possibly thiorid-
azine, the order of potency for inhibition of electron
transport was well correlated with the relative risk of
these drugs for causing TD.
3. Compensatory Changes in Mitochondrial Function
with Antipsychotic Drug Treatment. We were sur-
prised to find that some studies suggest that neuro-
leptics may reverse mitochondrial insufficiency in the
frontal cortex of patients with schizophrenia. This sug-
gestion may seem puzzling given the aforementioned
ability of the FGAs to inhibit mitochondrial respiration
but can be reconciled by distinguishing separate effects
of drug treatment on mitochondrial biogenesis versus a
direct effect on mitochondrial enzyme activity. Ultra-
structural studies of postmortem brain samples revealed
a reduction in the number of mitochondria in the cau-
date and putamen of patients with schizophrenia off
drugs compared with control subjects and near-normal
numbers of mitochondria in the striatum of a subset of
patients with schizophrenia taking drugs (Kung and
Roberts, 1999). In rats, long-term treatment with anti-
psychotics (haloperidol, fluphenazine, and clozapine)
caused a significant increase in mitochondrial cyto-
chrome c oxidase activity in the frontal cortex (Prince et
al., 1998). Mitochondrial cytochrome c oxidase activity
was also significantly increased in postmortem samples
from several regions of brain tissue from medicated pa-
tients with chronic schizophrenia (Prince et al., 2000).
These studies suggest that antipsychotic treatment may
normalize mitochondrial density in frontal cortex, pos-
sibly contributing to a reversal of schizophrenic symp-
toms by restoration of the capacity for oxidative energy
metabolism. This finding is a likely corollary of DA re-
ceptor blockade, as cells can adapt to altered energy
demands by adjusting the number and subcellular local-
ization of their mitochondria (Ben-Shachar and Laifen-
feld, 2004).
In summary, APDs show differential effects on inhi-
bition of the electron transport system, with FGAs con-
sistently showing greater inhibition of the electron
transport system compared with SGAs. The greater im-
pairment of mitochondrial function by FGAs has been
implicated in the development of extrapyramidal symp-
toms, such as tardive dyskinesia. Interestingly, the neg-
ative impact that some of the APDs may have on energy
metabolism seems to lead to compensatory changes in
activity of mitochondrial enzymes and the number
and location of mitochondria that may serve at least
temporally to restore the capacity for oxidative energy
metabolism.
G. Glucose Transport and Mechanism of
Neuroprotection
Many FGAs and SGAs inhibit glucose transport, al-
beit to varying degrees, but paradoxically SGAs have
been shown to stimulate neuronal growth and survival.
The activation of Akt and ERK signaling pathways may
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play an important role in stimulation of neuronal growth
and survival.
1. Antipsychotic Drugs Inhibit Glucose Transport.
Many APDs produce significant inhibition of glucose
transport in erythrocytes (Baker and Rogers, 1972) and
cultured neuronal and muscle cell lines (Dwyer et al.,
1999b, 2002). The FGAs, chlorpromazine and fluphena-
zine, are potent inhibitors of glucose transport, whereas
haloperidol and sulpiride are essentially inactive (Table
1). Among the SGAs, risperidone, ziprasidone, and clo-
zapine effectively block glucose transport, whereas olan-
zapine and quetiapine are somewhat less effective
(Ardizzone et al., 2001; Dwyer et al., 2002, 2003b); aripi-
prazole has not been evaluated to date. The drugs seem
to act by binding directly to the glucose transporter and
affect transport via GLUT1 and GLUT3 isoforms. With
longer incubation periods, the drugs significantly in-
crease the expression of GLUT1 and GLUT3 in cells,
perhaps as a consequence of relative glucose deprivation
(Dwyer et al., 1999b). Furthermore, olanzapine has been
shown to enhance cellular uptake of glucose (Dwyer et
al., 2003a).
2. SGAs Promote Neurite Outgrowth and Cell Sur-
vival—Role of Akt. In light of these effects on glucose
transport, the effects of APDs on cell growth are para-
doxical and reflect the dual nature of many of these
drugs. Thus, at low concentrations (10–50 M), cloza-
pine and quetiapine produce positive effects on neuronal
growth (Bai et al., 2002; Lu and Dwyer, 2005), whereas
at slightly higher concentrations, they adversely affect
cell viability. Chlorpromazine and fluphenazine are uni-
formly toxic for cells over the same concentration range.
On the other hand, olanzapine is mitogenic and neuro-
protective over a wide range of concentrations (Dwyer et
al., 2003a; Lu et al., 2004). Recently, some APDs have
been reported to protect neuronal cells against a variety
of insults (Bai et al., 2002; Qing et al., 2003; Lu et al.,
2004) and to promote neurite outgrowth in the PC12 cell
line (Lu and Dwyer, 2005). Other APDs produce the
opposite effects: inhibition of cell growth and neurite
extension (Dwyer et al., 2003a; Lu and Dwyer, 2005).
The nature of the cellular response to a particular drug
seems to depend on its overall biochemical profile, in-
cluding the degree of glucose transport inhibition, affin-
ity for calmodulin, mitochondrial toxicity, and ability to
activate signaling pathways (Akt and Src) that provide
trophic influences (Table 1).
It is not known how the specific APDs, particularly the
SGAs, produce these neurotrophic effects; however,
clues are beginning to emerge. Optimization of glucose
metabolism in cells or preferential use of glucose rather
than glutamine for energy is associated with decreased
susceptibility to harmful insults (Kan et al., 1994; Goos-
sens et al., 1996; Dwyer et al., 1999a; Moley and Mueck-
ler, 2000). Moreover, the SGAs, olanzapine, quetiapine,
and clozapine, stimulate phosphorylation (activation) of
the serine/threonine kinases, Akt and ERK (Lu et al.,
2004; Lu and Dwyer, 2005). Inhibition of Akt with a
selective antagonist abrogates the protective effects of
olanzapine on PC12 cells (Lu et al., 2004). In addition,
inhibition of Akt and ERK activation with LY294002
and PD98059, respectively, blocks the induction of neu-
rite outgrowth by olanzapine, quetiapine, and clozapine
(Lu and Dwyer, 2005). In contrast, fluphenazine, chlor-
promazine, and selective calmodulin antagonists inhibit
activation of Akt by olanzapine and nerve growth factor
(Lu and Dwyer, 2005), suggesting that calmodulin plays
a significant role in the trophic effects of this SGA. Thus,
with respect to activation of key signaling pathways
(Akt and ERK), the SGAs seem to have a more favorable
profile than the FGAs.
The role of Akt in the neuroenhancement produced by
SGAs is intriguing for several reasons. First, Akt is
downstream of the insulin receptor and regulates re-
cruitment of GLUTs to the cell surface (Hajduch et al.,
2001; Lawlor and Alessi, 2001). It also regulates the
production of glucose-6-phosphate dehydrogenase, the
rate-limiting step in the pentose phosphate pathway
(Hajduch et al., 2001; Lawlor and Alessi, 2001). The
pentose phosphate pathway provides NADPH to defend
the cell against oxidative stress (neuroprotection) and
for the synthesis of fatty acids (in support of neurite
TABLE 1
Biological profile of antipsychotic drugs
Inhibition of
Glucose Transporta
Calmodulin
Antagonismb
Activation
of Akt/Erkc Neuroprotection
d Enhancement of
Neurite Outgrowthe
Chlorpromazine     
Fluphenazine     
Haloperidol     
Clozapine     
Olanzapine  N.R.   
Quetiapine  N.R.   
Risperidone  N.R.   
Ziprasidone  N.R.  N.E. 
, intensity of drug activity; , no effect; N.R., not reported; N.E., not established.
Compiled from:
a Dwyer et al., 1999b; Ardizzone et al., 2001.
b Weiss et al., 1983; Roufogalis et al, 1983.
c Lu et al., 2004; Lu and Dwyer, 2005.
d Bai et al., 2002; Lu et al., 2004.
e Lu and Dwyer, 2005; Dwyer and Dickson, 2007.
386 LIEBERMAN ET AL.
outgrowth), nitric oxide, and neurotransmitters (Baquer
et al., 1988; Biagiotti et al., 2001). Second, Akt is broadly
involved in the regulation of cell growth, differentiation,
and survival (Hajduch et al., 2001; Lawlor and Alessi,
2001). Finally, Emamian et al. (2004) recently reported
an association between a particular haplotype of the
Akt1 gene and schizophrenia and found reduced levels of
Akt1 in the brain and peripheral blood lymphocytes of
patients with schizophrenia compared with control sub-
jects. Thus, therapeutic strategies with the aim of en-
hancing the activity of Akt or its downstream targets
may provide clinical benefits in schizophrenia.
In summary, APDs are associated with inhibition of
glucose transport, albeit to varying degrees. Somewhat
paradoxically, APDs can promote neurite outgrowth and
cell survival in cell cultures, a finding that is dependent
on drug and dose, degree of glucose transport inhibition,
affinity for calmodulin, mitochondrial toxicity, and the
ability to active the Akt and Src pathways. Overall,
SGAs seem to have a more favorable profile than FGAs.
H. Second-Generation Antipsychotic Drugs
Demonstrate Antioxidant Properties
The rat pheochromocytoma (PC12) cell line possesses
properties associated with neuroblasts and neurons and
is a well established model for studying the cellular
biology of neurons, including the mechanisms involved
in neurotoxicity, neuroprotection, and neuronal repair.
Exposure of cells to hydrogen peroxide induces a concen-
tration-dependent decrease in cell viability that was at-
tenuated by olanzapine treatment (Wei et al., 2003a).
-amyloid(25–35) peptide induces oxidative stress and ap-
optosis in PC12 cultures, which are prevented by olan-
zapine and quetiapine (Wei et al., 2003b; Wang et al.,
2005b). These findings suggest that some SGAs may act
as antioxidants and that this mechanism may be the
basis for part of their neuroprotective effects.
SOD1 reduces cellular oxidative stress and neuronal
damage by inactivation of oxygen free radicals (Fridov-
ich, 1986). The enzyme occurs in the large pyramidal
neurons of the hippocampus and cortex (Delacourte et
al., 1988; Ceballos et al., 1991) and its long-term inhibi-
tion produces apoptotic cell death of spinal neurons
(Rothstein et al., 1994). It has been shown that PC12
cultures treated with olanzapine show increased SOD1
gene expression (Li et al., 1999). Other SGAs, such as
clozapine, quetiapine, and risperidone were found to
modulate the expression of SOD1 in a similar fashion
(Bai et al., 2002). Inhibition of the mitochondrial oxida-
tive processes by the neurotoxin 1-methyl-4-phenylpyri-
dinium ion (MPP) reduces SOD1 gene expression, thus
increasing cell death, whereas SGAs protect the cultures
against MPP-induced cell death (Qing et al., 2003).
This effect was observed for the SGAs clozapine, olan-
zapine, quetiapine, and risperidone but not for the FGA
haloperidol.
A reduction in oxidative stress has also been observed
in patients undergoing APD therapy. Dakhale et al.
(2004) reported a significant increase in serum SOD and
serum malondialdehyde and a decrease in plasma ascor-
bic acid in patients with schizophrenia, and treatment
with SGAs significantly decreased serum malondialde-
hyde and increased plasma ascorbic acid levels. In addi-
tion, the levels of oxidative stress may differ in patients
being treated with FGAs versus SGAs. Kropp et al.
(2005) compared the levels of malondialdehyde in pa-
tients taking antipsychotic medications and found sig-
nificantly lowers levels of this marker of lipid peroxida-
tion in patients being treated with SGAs (clozapine,
quetiapine, amisulpride, and risperidone) compared
with treatment with FGAs (Kropp et al., 2005). How-
ever, not all studies have found differences between
FGAs and SGAs in oxidative stress parameters (Zhang
et al., 2006).
In summary, some of the SGAs have been shown to
increase cell viability in a number of experimental con-
ditions that are associated with cell death such as expo-
sure to hydrogen peroxide, -amyloid, or a mitochondrial
neurotoxin. SGAs also lead to a reduction in measures of
oxidative stress in patients with schizophrenia that tend
to be greater than that observed with FGAs.
I. Regulation of Neurogenesis and Neurotrophic Factor
Expression
In animal studies, APDs can modulate the levels and
expression of specific neurotrophin factors and modulate
neurogenesis and cell proliferation, with a number of
differences noted between FGAs and SGAs. There is
evidence for regulation of neurotrophin factors in pa-
tients treated with antipsychotic agents, although not
without controversy. Recent work in rodents has also
demonstrated a role for APDs in stimulating neurogen-
esis and cell proliferation.
1. Regulation of Neurotrophic Factor Expression. In
the rat, differential treatment effects of APDs (primarily
haloperidol, olanzapine, risperidone, and quetiapine)
have resulted in brain region-specific changes in the
levels of BDNF protein, BDNF mRNA, or the BDNF
receptor, TrkB (Table 2) (Angelucci et al., 2000b, 2005;
Dawson et al., 2001; Chlan-Fourney et al., 2002; Bai et
al., 2003; Fumagalli et al., 2003a; Parikh et al., 2004a).
Changes in the levels of NGF (Angelucci et al., 2000a,
2005) and basic FGF (Fumagalli et al., 2004) have also
been reported in rat brain with APD treatment. Data
indicate that less than 3 days of treatment with either a
FGA or SGA had little or no effect on the levels of any
neurotrophic factor, whereas 21 to 28 days of treatment
with haloperidol generally decreased the levels. In con-
trast, SGAs showed either no effect or a slight increase
in neurotrophic factor levels.
There has been a systematic investigation over the
last few years of the effects of APDs on the levels of NGF,
BDNF, and their respective receptors, TrkA and TrkB,
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in several regions of rat brain after 7, 14, 45, 90, and 180
days of treatment. The NGF and BDNF levels in rat
hippocampus, striatum, and sensory motor cortex were
significantly higher after a 7- or 14-day treatment with
haloperidol, olanzapine, or risperidone compared with
vehicle controls (S. Mahadik, unpublished observations).
The data from a 45- and 90-day treatment indicated that
haloperidol significantly reduced the NGF levels in rat
septum, hippocampus, nucleus basalis, and cortex, but
no change was found with risperidone, olanzapine, and
clozapine (Parikh et al., 2004b,c). Likewise, a 45-day
treatment with haloperidol, but not with olanzapine,
reduced hippocampal BDNF and its receptor TrkB levels
(Parikh et al., 2004a). Furthermore, switching rats after
45 days of treatment with haloperidol to risperidone or
clozapine for the next 45 days increased the NGF levels
from 25 to 70% (Parikh et al., 2004b), and switching
rats after 45 days of treatment with haloperidol to olan-
zapine increased BDNF levels comparable with the lev-
els observed in 90-day, vehicle-treated controls (Parikh
et al., 2004a). Finally, because NGF primarily regulates
cholinergic activity, the effects of antipsychotics on NGF
levels paralleled the levels of the cholinergic marker,
choline acetyltransferase (ChAT) (Parikh et al.,
2004b,c). The representative immunohistochemical data
from these studies are shown in Fig. 3.
Recently, Terry et al. (2006) reported that exposure of
rats to oral haloperidol or ziprasidone for 7 or 14 days
resulted in significant increases in NGF and ChAT im-
munoreactivity in the hippocampus. At 45 days, NGF
and ChAT immunoreactivity had decreased to control
levels in the ziprasidone-treated group but was mark-
edly reduced in rats treated with haloperidol. After 90
days, NGF and ChAT levels were substantially lower
than those of controls in both groups. Although exposure
to ziprasidone had less deleterious effects on NGF and
ChAT levels at 45 days, this beneficial effect was not
evident at 90 days.
Data from 90 and 180 days of antipsychotic treatment
in rats indicated that rat hippocampal BDNF levels
were not altered by treatment with olanzapine but were
significantly reduced by treatment with haloperidol (40
and 60% after 90 and 180 days, respectively), chlorprom-
azine (50% at both time points), and risperidone (20 and
40% after 90 and 180 days, respectively) (Pillai et al.,
2006). Moreover, hippocampal NGF levels were signifi-
cantly reduced (60%) with haloperidol and chlorprom-
azine, but only smaller reductions (20–30%) were found
TABLE 2
Regulation of neurotrophic factors by antipsychotic drug treatments in animals and schizophrenic patients
Treatment Factor/Region Effect Reference
Atypical
Clozapine (10 mg/kg, 28 days) BDNF/HP Decreased Lipska et al., 2001
Clozapine (20 mg/kg, 19 days) BDNF/HP No Effect Chlan-Fourney et al., 2002
Clozapine (27 mg/kg, 28 days) BDNF/HP Decreased Bai et al., 2003
Olanzapine (2.7 mg/kg, 28 days) BDNF/HP Increased Bai et al., 2003
Olanzapine (15 mg/kg, 30 days) BDNF/HP Decreased Angelucci et al., 2005
Olanzapine (10 mg/kg, 45 days) BDNF/HP No effect Parikh et al., 2004a
Risperidone (2.3 mg/100g food, 19 days) BDNF/HP, FrCtx Decreased Angelucci et al., 2000b
Risperidone (1 mg/kg, 19 days) BDNF/HP No effect Chlan-Fourney et al., 2002
Risperidone (4 mg/kg, 19 days) BDNF/HP Decreased Chlan-Fourney et al., 2002
Olanzapine (15 mg/kg) NGF/HP, OcCtx Increased Angelucci et al., 2005
Risperidone (2.3 mg/100g food, 19 days) NGF/HP, Striatum Decreased Angelucci et al., 2000a
Clozapine (10 mg/kg, 21 days) FGF2/PfrCtx, Striatum Increased Riva et al., 1999; Maragnoli et al., 2004
Typical
Haloperidol (1.15 mg/100g food, 19 days) BDNF/HP, FrCtx Decreased Angelucci et al., 2000b
Haloperidol (1 mg/kg, 28 days) BDNF/HP Decreased Lipska et al., 2001
Haloperidol (2 mg/kg, 21 days) BDNF/HP, FrCtx Decreased Nibuya et al., 1995
Haloperidol (1 mg/kg, 28 days) BDNF/HP Decreased Bai et al., 2003
Haloperidol (1 mg/kg, 19 days) BDNF/HP Decreased Chlan-Fourney et al., 2002
Haloperidol (2 mg/kg) BDNF/HP Decreased Parikh et al., 2004a
Haloperidol (1 mg/kg, 3 days) BDNF/Amy, Ctx Decreased Meredith et al., 2004
Ritanserin (2 mg/kg, 19 days) BDNF/HP (CA1) Decreased Chlan-Fourney et al., 2002
Eticlopride (3 mg/kg, 3 days) BDNF/Amy, Ctx Decreased Meredith et al., 2004
Haloperidol (1.15 mg/100g food, 19 days) NGF/HP, striatum Decreased Angelucci et al., 2000a
Haloperidol (1 mg/kg, 21 days) FGF2/striatum No effect Riva et al., 1999
Schizophrenia models
Ibotinic acid lesion BDNF/HP, PfrCtx Decreased Lipska et al., 2001; Ashe et al., 2002
MK-801 BDNF/HP Decreased Fumagalli et al., 2003b
MK-801  quetiapine BDNF/HP Normalized Fumagalli et al., 2003b
MK-801  haloperidol BDNF/HP Decreased Fumagalli et al., 2003b
Stress BDNF/HP Decreased Smith et al. 1995; Luo et al, 2004
Stress  olanzapine BDNF/HP Increased Luo et al., 2004
Postmortem
Schizophrenic BDNF/Ctx Decreased Durany et al., 2001
Schizophrenic BDNF/PfrCtx Decreased Weickert et al., 2003, 2005
Schizophrenic BDNF/Serum Decreased Toyooka et al., 2002
Schizophrenic BDNF/Serum No effect Shimizu et al., 2003
Schizophrenic BDNF/Serum Decreased Tan et al., 2005
HP, hippocampus; OcCtx, occipital cortex; FrCtx, frontal cortex; Amy, amygdala; CTx, cortex; PFRCtx, prefrontal cortex.
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with olanzapine and risperidone. In contrast, levels of
both striatal BDNF and NGF were very significantly
reduced (75–90%) by treatment with all of the APDs
after 90 and 180 days (90  180). Of interest, even
though treatment with olanzapine or risperidone for 180
days very significantly reduced (80–90% versus con-
trols) the levels of striatal BDNF and NGF, these anti-
psychotics very effectively restored the levels (60–70% of
controls) in animals treated with haloperidol for 90 days
when they were switched to olanzapine or risperidone
for the next 90 days (total 180 days). However, the
mechanisms involved in reducing neurotrophic levels
and those involved in elevating neurotrophic levels after
a switch from haloperidol to olanzapine or risperidone
are not known.
Erythropoietin (EPO) and its receptor, EPOr, are
highly expressed within neuronal, glial, and endothelial
cells in the brain, and they have been thought to play a
role in neuroprotection (Bernaudin et al., 1999, 2000;
Brines et al., 2000; Sire´n et al., 2001; Marti, 2004). In
the rat brain, 14 days of exposure to haloperidol in-
creased both EPO and EPOr in the hippocampus; how-
ever, after 45 days of exposure to haloperidol, the levels
were decreased significantly relative to day 14 (Pillai
and Mahadik, 2006). In contrast, olanzapine treatment
for 14 and 45 days resulted in elevations in the levels of
EPO and EPOr in both brain regions in the rat, and EPO
levels in the hippocampus were significantly increased
at day 45 compared with those at day 14.
SGAs can also ameliorate the reductions in neurotro-
phins observed after various experimental paradigms.
For example, immobilization stress decreases BDNF
protein levels and BDNF immunoreactivity in the rat
hippocampus, and the stress-induced BDNF reductions
were attenuated by long-term administration of quetia-
pine (Xu et al., 2002). In addition, quetiapine has been
shown to up-regulate FGF-2 and BDNF expression in
rat hippocampus when NMDA receptors were blocked
(Fumagalli et al., 2004). Similar effects were observed
with olanzapine, but not with haloperidol, providing a
further link between SGAs and neurotrophic responses
(Fumagalli et al., 2003b).
How APDs affect neurotrophin levels is not well un-
derstood. For example, DA D2 receptor activation has
been shown to up-regulate FGF-2 expression within the
rat brain (Heckers et al., 1991; Swayze et al., 1992).
Likewise, in cell cultures, dopamine and dopamine re-
ceptor agonists increased neurotrophic factor expression
(Ku¨ppers and Beyer, 2001; Guo et al., 2002; Ohta et al.,
2003). These observations suggest that APDs by virtue
of their DA D2 receptor antagonism would inhibit neu-
rotrophin expression albeit to varying degrees, reflect-
ing their binding affinities for the DA D2 receptor, dis-
sociation rates, and doses used. There is evidence that
haloperidol can block the expression of BDNF by DA D2
agonists (Okazawa et al., 1992). In addition, high, but
not low, doses of clozapine or risperidone that are known
to markedly block DA D2 receptors also decrease the
CO
N 
CLO
Z 
HAL RISP
5 6 7 8
CLOZ / HAL HAL / CLOZRISP / HAL HAL / RISP
FIG. 3. Differential effects of 90-day treatment with FGAs [haloperidol (HAL)] and SGAs [risperidone (RISP) and clozapine (CLOZ)] on cerebral
cortical NGF and ChAT. Animals received each drug (HAL  2 mg/kg/day; RISP  2.5 mg/kg/day; CLOZ  20 mg/kg/day) in drinking water
continuously for 90 days. Some animals treated with HAL for 45 days were switched to either RISP (HAL/RISP) or CLOZ (HAL/CLOZ) administration,
and some animals with RISP and CLOZ administration for 45 days were switched to HAL treatment (RISP/HAL and CLOZ/HAL, respectively) for the
next 45 days to investigate the restoration or prevention, respectively, of HAL-induced reduction of NGF and ChAT. Plasma levels of drugs were
similar to plasma drug levels reported in patients with schizophrenia at therapeutic doses, and all the immunohistochemical procedures were done
as described previously (Parikh et al., 2004a). Immunohistograms show NGF (red) in cortical neuronal cell bodies that are surrounded by cholinergic
projections (ChAT, green) of cholinergic neurons from nucleus basalis. CO (vehicle-treated) shows dense localization of NGF and ChAT. HAL shows
very significant reductions in both NGF and ChAT. However, RISP shows a slight reduction, whereas no reduction was found with CLOZ.
Furthermore, post-treatment with RISP or CLOZ shows significant restoration (HAL/RISP  HAL/CLOZ) of HAL-induced reduction of NGF and
ChAT. Likewise, pretreatment with RISP or CLOZ shows significant prevention (RISP/HAL  CLOZ/HAL) of HAL-induced reduction of NGF and
ChAT. The detailed quantitative data were reported earlier (Parikh et al., 2004a,b).
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expression of BDNF in the hippocampus (Chlan-Four-
ney et al., 2002). Another factor may involve the inter-
action of the SGAs with a number of other neuronal
receptors including 5-HT2 receptors, as the selective
5-HT2 receptor antagonist ritanserin increases the ex-
pression of hippocampal BDNF (Chlan-Fourney et al.,
2002).
A reduction in neurotrophin levels has been observed
in patients with schizophrenia, but only a few studies to
date have demonstrated a selective role for SGAs in
ameliorating these changes. For example, plasma NGF
levels in patients with chronic schizophrenia treated
with atypical antipsychotics were significantly higher
than the levels observed in patients treated with FGAs
(Parikh et al., 2003). Another study reported that serum
BDNF levels in patients treated with clozapine were not
significantly higher than values from patients treated
with typical antipsychotics (Grillo et al., 2007), although
serum BDNF levels were strongly and positively corre-
lated with the dose of clozapine (Grillo et al., 2007).
These findings are consistent with an earlier study re-
porting reductions in basal NGF levels in neuroleptic-
free patients with schizophrenia subsequently treated
with haloperidol (Aloe et al., 1997). Other studies,
though, have not shown increases in neurotrophin levels
after treatment with SGAs (Pirildar et al., 2004; Tan et
al., 2005). Of interest, there is evidence for elevation of
NGF serum concentrations in APD-naive patients with
schizophrenia who were and were not substance abus-
ers. Furthermore, reductions (or normalization) in NGF
levels has been reported with APD treatment (Jockers-
Scheru¨bl et al., 2006). These disparate findings may
reflect to some degree complexities surrounding the
presence of comorbid substance abuse, environmental
factors such as stress, and the potential for endogenous
compensatory changes within the brain.
2. Regulation of Neurogenesis and Cell Proliferation.
One mechanism that has generated a great deal of in-
terest is the regulation of cell proliferation and neuro-
genesis in the adult brain. Recent studies demonstrate
that neural progenitor cells continue to divide and give
rise to new neurons in the subgranular zone of the
hippocampus and the subventricular zone. Increased
neurogenesis, cell migration to target sites, and differ-
entiation into mature neuronal and glial phenotypes
have been reported in the adult rodent brain under a
variety of pathophysiological conditions (Dawirs et al.,
1998; Gould et al., 1999; Nilsson et al., 1999; Madsen et
al., 2000; Malberg et al., 2000; Wakade et al., 2002;
Halim et al., 2004; Kodama et al., 2004; Wang et al.,
2004b; Kippin et al., 2005). The rate of proliferation and
survival of new neurons is a dynamic process regulated
by neuronal activity and environmental and endocrine
factors (Duman, 2004). In addition to neurogenesis, pro-
liferation of glia, including astrocytes and oligodendro-
cytes and endothelial cells, takes place throughout the
adult brain.
Recent studies demonstrate that neurogenesis and
cell proliferation in the rodent brain are regulated by
various psychotropic drugs, including APDs (Duman,
2004; Kodama et al., 2004), although the findings for
FGAs have been controversial. After 4 days of treatment
with haloperidol (5 mg/kg) followed by labeling of new-
born cells for 7 days with bromodeoxyuridine (BrdU),
the marker for cell proliferation, an increase in dentate
granule cell proliferation was seen in gerbil hippocam-
pus (Dawirs et al., 1998). Likewise, 3 days of haloperidol
(2 mg/kg) administration followed by labeling of new-
born cells with BrdU and subsequently analyzing la-
beled cells surviving after 28 days with continuous ex-
posure to haloperidol was found to increase neural stem
cell proliferation in rat brain (Kippin et al., 2005). In
contrast, a 28-day study of haloperidol (2.0 mg/kg/day)
followed by labeling of proliferating cells with BrdU and
analyzing them either immediately or 21 days later with
continuing drug exposure for determination of cell sur-
vival showed no increased proliferation or survival in
hippocampal dentate gyrus (Halim et al., 2004). Another
study with 21 days of exposure to haloperidol (2.0 mg/
kg/day) followed by labeling of proliferating cells with
BrdU and analyzing immediately or analyzing for cell
survival 14 days later with or without haloperidol ad-
ministration also demonstrated no increased prolifera-
tion or survival (Wang et al., 2004b). More recently, the
temporal course of cell proliferation was investigated
after continuous exposure to haloperidol for 7, 14, 21,
and 45 days at doses 0.05 and 2.0 mg/kg/day (S. Ma-
hadik, unpublished observations). Compared with vehi-
cle treatment, haloperidol (2.0 mg/kg/day group) had
increased the number of proliferating cells at the 7th
day, which reached a maximum (2- to 3-fold) at the 14th
day. However, cell proliferation returned to control lev-
els at the 21st day and was significantly reduced (halo-
peridol 0.5 mg/kg  25% and haloperidol 2 mg/kg 
5% of controls) at the 45th day. Data on the survival of
the 14th day BrdU-labeled cells for the next 28 days on
continuous exposure to haloperidol indicated that these
cells do not survive.
The effects of SGAs on cell proliferation in the adult
rodent brain have been more consistent. Both olanzap-
ine and risperidone significantly increased cell prolifer-
ation in the subventricular zone and hippocampus after
21 days of treatment (Wakade et al., 2002). In other
studies, olanzapine treatment for 21 days was also re-
ported to cause 2- to 4-fold increases in cell proliferation,
depending on the rat brain region examined (Kodama et
al., 2004; Wang et al., 2004b; Green et al., 2006). Rep-
resentative data on the effects of haloperidol and olan-
zapine on cell proliferation are shown in Fig. 4.
The formation of new neurons in the hippocampus is
significant as adult rat brain neurogenesis has been
consistently observed with both pharmacological and
nonpharmacological antidepressant therapies (Madsen
et al., 2000; Malberg et al., 2000) and seems to be func-
390 LIEBERMAN ET AL.
tionally important in the behavioral effects of antide-
pressant drugs observed in mice (Santarelli et al., 2003).
APDs seem to produce similar effects to varying degrees.
The increase in cell proliferation in the prefrontal cortex
and striatum leads to increased numbers of endothelial
cells and oligodendrocytes, as well as a subpopulation of
unidentified cells (Kodama et al., 2004). The increase in
oligodendrocytes could contribute to a reversal of white
matter loss that has been reported in patients with
schizophrenia (Hakak et al., 2001; Davis et al., 2003). In
addition, increased striatal and cortical cell proliferation
could contribute in part to increased gray matter and
also reflects the ability of these antipsychotic agents to
either protect against cell loss or to confer beneficial
increases in endothelial cell number.
In summary, a number of studies have demonstrated
differential effects of APDs on the level and expression of
specific neurotrophin factors and their receptors within
the rodent brain, and some evidence exists for regulation
in patients with schizophrenia also. In addition, APDs
can stimulate neurogenesis and cell proliferation in the
adult rodent brain. However, to date the studies point-
ing to APD effects on neurogenesis have been performed
predominantly in nonprimate species, and there are no
data to support survival of newly generated neurons in
the adult primate forebrain (Bhardwaj et al., 2006). Ad-
ditional work will be necessary to determine whether
the regulation of neurogenesis and cell proliferation
with APDs occurs within the adult nonhuman primate
forebrain and is a mechanism that exists in humans.
IV. Conclusions
Schizophrenia entails a progressive pathophysiologi-
cal process that possibly involves a limited neurodegen-
erative component, which causes the clinical deteriora-
tion that historically has been the hallmark of the
illness. In this article, we reviewed studies of the effects
of APDs, including FGAs and SGAs, on a number of
assays and mechanisms pertinent to the pharmacother-
FIG. 4. Differential temporal effects of haloperidol (HAL) and olanzapine (OLZ) administration on cell proliferation in hippocampus of adult rat
brain. Animals were treated with vehicle, HAL or OLZ, as described in Fig. 4 for 14 and 45 days. All procedures were as described in Wakade et al.
(2002). Newly born cells were labeled with bromodeoxyuridine (BrdU) and visualized with DAB immunostaining staining (brown dots), and then
stained cells were counted. A, top shows the representative immunohistograms of control-14 day, HAL-14 day, and olanzapine-14 day; bottom shows
the control-45 day, HAL-45 day, and olanzapine-45 day. Most of the proliferating cells are in the hilus and subgranular zone of the dentate gyrus. The
inset in olanzapine-45 day shows a higher magnification of a group of BrdU-positive cells. B, differential temporal effects on the numbers of
proliferating cells (, p  0.001 versus vehicle).
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apy of schizophrenia (Fig. 5) in an attempt to under-
stand the clinical implications of the range of pharma-
cological effects demonstrated by these various
paradigms. Many studies have now shown that some
APDs, particularly those of the SGA class, can enhance
neural cell functions, resilience, and plasticity. These
observations may have potential clinical relevance, be-
cause they suggest the different cellular mechanisms by
which some APDs may exert effects beyond those that
are traditionally measured through neuroreceptor bind-
ing or neurotransmitter release and immediately ob-
servable behaviorally, which may be able to ameliorate
the pathophysiological progression of this illness.
With some variation, SGAs display unique pharmaco-
logical actions that may distinguish them from FGAs. In
both traditional animal models and neurochemical mod-
els and with regard to receptor binding profiles, SGAs
display a pattern of activity that predicts antipsychotic
activity with a reduced liability to produce EPS. This
pattern has been consistently associated with a greater
potential for pharmacological activity in novel brain re-
gions such as temporolimbic and prefrontal cortices. In
addition, the SGAs variably enhance levels of DA, nor-
epinephrine, 5-HT, ACh, and glutamate (aspartate),
whereas they decrease efflux of GABA. Enhancement of
monoamine levels has been shown to increase neurotro-
phic factors.
SGAs can reduce caudate hypertrophy observed in
patients treated with FGAs, and recent data indicate a
significant role of SGAs in limiting the loss of gray
matter and dendritic remodeling. The molecular under-
pinning of dendritic remodeling is the subject of consid-
erable scrutiny, with different players such as receptors,
growth factors, and GTPases being examined. It will
important to determine the cytoskeletal structure of
neurons in future studies of how APDs influence these
factors.
In a variety of model systems, some of the SGAs are
more effective than the FGAs in attenuating the effects
of noncompetitive NMDA receptor antagonists. Some
SGAs induce neuroactive steroids that may result in
actions that enhance GABAergic neurotransmission and
offer neuroprotective and neurotrophic effects. Some
SGAs can reduce oxidative stress in animal models of
neurotoxicity and potentially in patients with schizo-
phrenia. Some SGAs but not FGAs show the ability to
block and, in some instances, reverse neurodegenerative
processes associated with apoptosis and excitotoxicity in
animal models of neurodegeneration. It is clear that
FGAs have much greater potential than do SGAs to
inhibit oxidative phosphorylation directly in vitro. Some
SGAs, by virtue of their effects on glucose metabolism,
Akt, and neurite outgrowth, may also offer a new mech-
anism for therapeutic effects and prevent the neurode-
generative effects that seem in the course of the illness.
The possibility that some SGAs might limit neurode-
generative processes and effects that occur in the brains
of patients with schizophrenia is exciting and offers hope
in limiting the cumulative morbidity of patients with
schizophrenia and reducing the burden of disease for
patients and their families. Furthermore, studies of the
neuroprotective effects of APDs may reflect another
mechanism of action that APDs can act through that is
clinically relevant and should stimulate the search for
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FIG. 5. Generalization of comparative changes of FGAs and SGAs on physiological processes thought to be dysfunctional in schizophrenia. These
comparative observations are based on either changes found in patients with schizophrenia or inferred from in vitro or animal studies cited in this
review. In some instances, the effects of the drugs within the class differ, and this is denoted by the use of two symbols. NC, no change; , increase
or improvement; , decrease or decline.
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new drugs for schizophrenia with novel mechanisms
beyond the more familiar effects current drug treat-
ments have on the monoaminergic neurotransmitter
systems.
As pointed out in this critical review of the literature
on the effects of APDs, there is inconsistency in the
results of these different studies and many instances of
interstudy variability of the biological effects between
the FGA and SGA drug classes and also variation within
each of the two drug classes. Research is new and lim-
ited in some of the areas reviewed, and technical proce-
dures have not been standardized, which contributes to
variability. In addition, many studies use only haloper-
idol as the FGA and not all of the SGAs have been fully
evaluated. It is difficult in animal studies to be sure that
clinically equivalent doses of the APDs are adminis-
tered. Many studies were short-term in nature, and of-
ten subchronic studies were relatively short-term. These
factors make extrapolation of these results to the effects
of APDs in humans after weeks or months of treatment
difficult at best. Furthermore, many of the biological
processes evaluated in cell lines and in animals have not
been fully characterized in humans, and their clinical
relevance is not known. Consequently, the impact of
alterations of these processes in patients is unknown.
Clearly, more work is needed, but the bulk of the data
supports our tentative conclusion that some APDs,
mainly of the SGA group, may have effects that can be
therapeutic on many biological processes and neuropro-
tective on the pathophysiology of schizophrenia,
whereas the FGAs are neutral and in high doses may
even promote neurodegeneration. Therefore, we believe
that there may be clinical benefits in the use of selective
SGAs versus FGAs for long-term treatment particularly
in the early stages of schizophrenia and related psy-
chotic disorders.
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Correction to “Antipsychotic Drugs: Comparison in Animal
Models of Efficacy, Neurotransmitter Regulation,
and Neuroprotection”
The above article [Lieberman JA, Bymaster FP, Meltzer HY, Deutch AY, Duncan GE, Marx
CE, Aprille JR, Dwyer DS, Li XM, Mahadik SP, Duman RS, Porter JH, Modica-Napolitano
JS, Newton SS, and Csernansky JG (2002) Pharmacol Rev 60:358–403] contains errors.
On page 358, in the second paragraph of the footnote, the initials should be “C.E.M.”
On page 371, left column, first paragraph of section II.D, Altered Levels of Neuroactive
Steroids, the phrase “In addition to the classic effect of steroids on gene transcription via
binding to intracellular receptors,” has been deleted. The sentence now begins “Neuroactive
steroids can alter….” On the same page, in the right column, the very first reference citation
has been changed from “Shulman and Tibbo, 2005; Marx et al., 2006b” to “Paul and Purdy,
1992; Belelli and Lambert, 2005.” In the next paragraph, the citation “Marx et al., 2006b” has
been moved earlier in the sentence, from after the word “receptor” to after the word “con-
centrations.” At the end of the third full paragraph in the right column, the reference citation
“Harris et al., 2001” has been deleted. Finally, the fourth full paragraph, beginning “Neuro-
active steroids and neurosteroids are…” has been deleted in its entirety.
On page 384, the last full paragraph in the right column, beginning “Given that cholesterol
serves…,” has been deleted in its entirety.
On page 385, at the end of the last sentence of the last paragraph in the left column before
the beginning of section II.F, Effects of Antipsychotic Drugs on Mitochondria and Oxidative
Phosphorylation, the words “and activity” have been deleted.
The following references have been deleted: on page 394, Atmaca et al., 2002; on page 397,
Harris et al., 2001; on page 399, Marcinko et al., 2004, 2005, and 2007; and on page 401,
Procyshyn et al., 2007.
The following references have been added:
On page 394, “Belelli D and Lambert JJ (2005) Neurosteroids: endogenous regulators of the
GABAA receptor. Nat Rev Neurosci 6:565–575.”
On page 400, “Paul SM and Purdy RH (1992) Neuroactive steroids. FASEB J 6:2311–2322.”
The online version of this article has been corrected in departure from the print version.
The authors regret these errors and apologize for any confusion or inconvenience they may
have caused.
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